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ABSTRACT
CD98 is a multifunctional glycoprotein that is involved in various biological processes
such as amino acid transport and cell adhesion, diffusion, and proliferation. Non-alcoholic fatty
liver disease (NAFLD) is characterized by excessive lipid hepatic accumulation. The role of CD98
in NAFLD has not thoroughly been examined and there are limited reports in the literature with
regards CD98 relation to liver disease. Here, we investigated whether a reduction of CD98 expression mediated by CD98 siRNA-loaded nanoparticles (NPs) and plant derived nanovesicles could
attenuate liver disease markers in a mouse model of NAFLD. The nanoparticles strongly decreased
all markers of NAFLD, including the blood levels of ALT and lipids accumulation, fibrosis evidence and pro-inflammatory cytokines. Treatment with the plant nanovesicles attenuated

inflammation and steatosis in the mouse NAFLD model. In conclusion, our results indicate that
CD98 appears to function as a key actor/inducer in NAFLD, and that our NPs approach may offer
a new targeted therapeutic for this disease.
Exosomes are nanovesicles that are secreted by cells and participate in intercellular communication via exchange of cargo such as oligonucleotides, lipids, proteins, and peptides. Lately
the role of tumor derived exosomes has been questioned for aiding metastasis as some tumor derived exosomes participate in developing cellular environments that support metastasis in various
organs. Patients suffering from colorectal cancer commonly develop liver metastasis, thus the
role of exosomes from colorectal cancer could participate in the development of metastasis in the
liver. Our results demonstrated that exosomes derived from Caco2 BBe can increase integrin signaling which can contribute to metastasis or more tumorigenic phenotype.
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1

BACKGROUND

NAFLD
The liver is an important organ that is involved in carbohydrate metabolism, lipid metabolism, protein and amino acid metabolism, synthesis of plasma proteins, digestion, disposal of
drugs, toxins, and hormones, and phagocytosis. It isn’t surprising that treatment of liver diseases
is very important. Some diseases that occur in the liver are fatty liver disease (FLD), nonalcoholic steatohepatitis (NASH), hepatitis B and C, fibrosis, cirrhosis, and hepatocellular carcinoma
(HCC). FLD can be classified into two types: nonalcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease. NAFLD is very common in adults and children in the western society
due to the high fat western diets and is defined as lipid accumulation, steatosis, in the liver by
nonalcoholic means. [1, 2]. The pathogenesis of NAFLD is poorly understood, but what is
known is that it relates highly to metabolic syndrome (MetS) and insulin resistance [3]. There are
multiple proposed pathways for NAFLD pathogenesis. One such model is called the “Multi-hit”
hypothesis: 1) Insulin resistance induces dysregulated free fatty acid metabolism which results in
steatosis. 2) Inflammatory mediators, ROS, and dysregulated apoptosis result in the progression
to NASH. 3) Activation of stellate cells, reduction of hepatic regeneration, and increase hepatocyte death lead to fibrosis. 4) Regeneration capacity exhausted leads to cirrhosis [3]. Another
model suggests that insulin resistance in adipose tissue will increase FFA, adipocytokines, and
decrease adiponectin to develop steatosis [2]. Treatment for NAFLD is underdeveloped due to its
asymptotic nature. Interest in NAFLD has recently gained momentum due its potential progression to fibrosis, cirrhosis, and hepatocellular carcinoma (Scheme 1). Treatments that are being
investigated are insulin sensitizers, antioxidants, hepatocyte-protective agents, antidyslipidemias,
RAS blockers, incretin-related agents, and antiobesity drugs [4]. However, currently there is no
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an approved drug on the market that treats NAFLD and lifestyle changes such as exercise and
diet remain the most effective at reducing the risk of the disease progressing [2].

Scheme 1: Multi-hit hypothesis and pathogenesis of NAFLD
Nanoparticles
1.2.1

Background

Nanotechnology is a multidisciplinary field that integrates biology, chemistry, engineering,
physics, and medicine. The nanomaterials (NMs) have been applied in multiple aspects in industry,
medicine, energy, health care, agriculture, and electronics [5]. More attention has been given to
nanoparticles (NPs) for use as a therapeutic delivery system. Conventional drug delivery methods
such as orally administered pills and intravenous injection lack specificity, tunable drug release,
and are usually accompanied by various side effects. Another issue facing common therapeutics is
the poor solubility. NPs as delivery systems have been shown to improve specificity have tunable
drug release to improve the half-life of therapeutics and have promising potential to reduce the
cytotoxicity of drugs [6]. Typically, NPs range from 2 nm-500 nm in diameter and have various
morphologies. NPs are not a new idea of modern science. Artisans in the 9th century Mesopotamia
used them to create glittering effects. The first scientifically documented report of NPs was by
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Michael Faraday which involved gold NPs in 1847 [7]. It is debated that the explosion of modern
NP research was instigated by Richard Feynman when he gave his lecture, “There's Plenty of
Room at the Bottom,” given in December 1959 at Caltech where he discussed the issues surrounding manipulating and controlling things on a small scale which was later published in February
1960 [8]. Since then NPs have diversified to have many different formulations and applications.
Nanoparticles can be separated in types based on their composition and subcategorized
based on the shape and size. The common types of nanoparticles are inorganic NPs, polymeric
NPs, solid lipid NPs, liposomes, nanocrystals, nanotubes, and dendrimers [9]. Nanoparticles used
as therapeutic delivery systems share common strategies. Each nanoparticles formulation will either encapsulate or covalently bind the drug to the surface in order to coordinate a safe delivery to
the specific target and provide protection or improve solubility for the therapeutic [10]. Nanoparticles can have surface modifications that will increase targeting efficiency. These modifications
can range from ligands for receptors to antibodies [11, 12]. Not all nanoparticles share the biodegradability properties of others and can lead to accumulation and cytotoxicity. An example of
this is that inorganic NPs commonly lack biodegradation, while lipid-based and polymer NPs are
biodegradable [9, 13-15]. Based on this, dosing amounts and biocompatibility are very important
when designing the nanotherapeutic system. To date, the FDA has approved over 50 nanoparticles
for administration for various diseases [16].
1.2.2

Nanoparticle uses in NAFLD treatment

Nanoparticle use in liver pathologies range from delivering therapeutics to enhancing imaging potential. Common strategies for targeting NAFLD and NASH is to deliver anti-steatosis
and anti-inflammatory therapeutics to the liver. Liver fibrosis nanoparticles commonly include
anti-fibrotic therapeutics which can reduce inflammation and ROS species within the liver.
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Targeting activated stellate cells that are involved in generating liver fibrosis is also common. In
HCC, nanoparticles are often associated in delivering common chemotherapeutics and combatting
the inflammation and other detrimental effects associated to HCC. The liver itself is a primary site
for nanoparticle accumulation. A wide range of nanoparticle reports in association to early stages
of liver disease are described below.
To date, there are not many reports on the use of nanoparticles in NAFLD and NASH
when compared to the more serious conditions of fibrosis, cirrhosis, and hepatocellular carcinoma.
The common trend of the NPs used for treating NAFLD is to reduce lipid accumulation and overall
steatosis. Resveratrol-loaded PLGA NPs have been reported to increase the bioavailability of
resveratrol in cell culture and reduced lipid accumulation of oleic acid treated HepG2 cells in vitro
[17]. Polylactic acid nanoparticles loaded with CD98-siRNA exhibited reduced steatosis HFD
mice in addition to being anti-inflammatory [18]. Polyurethane NPs loaded with fenofibrate exhibited large reductions in oleic acid uptake in HepG2 cells and lipid content in MCD fed mice
[19]. Chitosan-functionalized lipid polymer hybrid nanoparticles, NPs with a polymer core and
phospholipid shell, loaded with silymarin reduced serum levels of ALT, AST, Cholesterol, and
triglycerides in addition to reduced lipid accumulation in the livers of HFD mice [20]. Fenofibrateloaded nanoliposomes formulations using soybean lecithin, cholesterol, and FNB increased the
bioavailability of fenofibrate and reduced the lipid accumulation in MCD fed mice [21]. From
these reports polymer and lipid-based nanoparticles have shown potential for delivering therapeutic agents to hepatocytes and the liver. Though some nanoparticle formulations were reported to
aggravate FLD. Silver nanoparticles stimulated a pro-inflammatory response from Kupffer cells
to induce inflammation in hepatocytes in HFD mice which may be associated to the transition of
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NAFLD to NASH [22]. This provides an example of damage associated to the accumulation of
nonbiodegradable NPs.
Nonalcoholic steatohepatitis (NASH) is a liver disease associated to inflammation (hepatitis) due to the damage of prolonged steatosis causing lipotoxicity and oxidative stress [23]. Current treatments for NASH are similar to NAFLD which aim to reduce steatosis, regulate metabolic homeostasis, prevent profibrotic mechanisms, and reduce inflammation [24, 25]. Nanoparticle treatments directly associated to NASH are very limited. Among these, PLGA nanoparticles
loaded with a SYK inhibitor demonstrated ameliorated fibrosis, inflammation, and steatosis in
mice possibly through targeting M1-differentiated inflammatory macrophages [26]. To combat
oxidative stress, redox nanoparticles consisting of redox polymers were tested on a NASH mouse
model which exhibited reduction in oxidative stress, inflammation, and fibrotic markers [27].
There were also reports of nanoparticles being used to enhance the diagnosis of NASH through
the use of modified Fe3O4 nanoparticles as contrast agents for MRI detection [28, 29].
Liver fibrosis is indicated by accumulation of extracellular matrix proteins in the liver after excessive damage from the OS, lipotoxicity, and inflammation in NASH or another chronic
liver disease which will eventually lead to hepatocellular dysfunction or cirrhosis [30]. The earliest reports of nanoparticle use in liver fibrosis was reported in the early 1990s where iron oxide
NPs were used as MRI contrast agents [31]. Expansion into using nanoparticles for treating hepatic fibrosis was later developed in the late 2000s. Mannose 6-phosphate-modified BSA nanoparticles loaded with sodium ferulate were developed to target the insulin-like growth factor 2
receptor on activated hepatic stellate cells [32]. Salvianolic acid B loaded mesoporous silica nanoparticles were shown to be beneficial for inhibiting ROS and proliferative activity of LX-2
cells [33]. Chitosan NPs loaded with hepatocyte growth factor promoted liver regeneration by
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upregulating the expression of MMP9 and MMP2 and promoted the transformation of mesenchymal stem cells into liver parenchymal cells [34]. Cationic solid lipid NPs were used to deliver
siRNA for connective tissue growth factor (CTGF) which resulted in reduced TGFβ, IL-6, and
CTGF [35]. Polymer NPs formed from mPEG-b-P(CB-co-LA) loaded with vismodegib (Hedgehog inhibitor) and rosiglitazone (PPAR-γ agonist) which resulted in reduced NFκB, TNF-α, and
IL-6 [36]. Silymarin loaded solid lipid NPs were reported to reduce hepatotoxicity through the
increased bioavailability of silymarin to downregulate Bcl-2, BAx, and PCNA [37]. Cerium oxide NPs were designed to act as free radical scavengers in order to reduce oxidative stress and
inflammation in rats with liver fibrosis [38]. A liposome functionalized AMD3100 octahydrochloride hydrate (CXCR4 antagonist) for targeting and loaded with VEGF siRNA to reduces fibrogenesis ameliorated CCl4 induced liver fibrosis [39]. Curcumin-encapsulated hyaluronic
acid–polylactide NPs were designed to target the hyaluronic acid receptor CD44 to deliver curcumin to activated hepatic stellate cells which resulted in attenuated tissue collagen production
[40]. Phosphatidylserine-decorated nanoparticles loaded with curcumin were shown to promote
the expression of MMP2 and hepatic growth factors [41]. Gold NPs were also used to deliver
curcumin to NIH/3T3 cells [42]. In vitro tests on LX-2 cells of titanium dioxide (TiO2) nanoparticles (NPs) and silicon dioxide (SiO2) NPs exhibited intrinsic antifibrotic properties in a dose
dependent manner [43]. Cyclic peptide pPB-modified sterically stabilized liposomes were shown
to be able to target activated hepatic stellate cells to induce apoptosis [44]. Neutral gold NPs
were used to decrease profibrotic and proinflammatory cytokines in Rats with fibrosis from alcohol-methamphetamine [45]. Chitosan NPs loaded with JQ1 and atorvastatin reduced hepatic stellate cell activation in CCl4 fibrotic mouse models [46].
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Exosomes
1.3.1

Background

Exosomes are nano-sized vesicular bodies that are excreted from a variety of cells. Exosomes come in a wide array of sizes from 20 – 200 nm. Exosomes have a cargo of nucleic acids
such as mRNA, miRNA, siRNA and also carry a varied array of proteins such as membrane
transport and fusion proteins, tetraspannins, heatshock proteins, proteins associated to metabolism and coagulation, adhesion proteins, ect [47]. The first documented journal of excreted vesicular bodies was reported during reticulocyte maturation [48]. It was later determined that this excretion was a method of removing proteins that were no longer necessary [49]. The role of exosomes has expanded since their first discovery. Reports have shown that exosomes play a role in
intercellular communication [50], cancer development [51], antimicrobial defense [52], immune
response [53], and various other functions. Exosomes have been studied as a tool for their diagnostic and therapeutic potentials for disease as well [47]. Research has primarily been performed
on mammalian derived exosomes and their interaction with various mammalian cells. The mechanism of how these exosomes are delivered to a recipient cell is poorly understood. However, the
method of delivery could follow endocytosis into the recipient cell, fusion into the membrane of
the recipient cell, or phagocytosis [54].
1.3.2

Plant Derived Exosomes

The first documented report of nanosized vesicular bodies from plants was published in
2006. An et al reported that barley leaves excreted paramural bodies which were similar to animal exosomes during fungal attack by powdery mildew fungus as a defense mechanism to prevent fungal penetration [55]. Similar results were reported with encasement and excretion of
powdery mildew fungus in Arabidopsis [56]. The reports demonstrated that the vesicles were
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excreted out of the plant cells after fungal attack using transmission electron microscopy. PDEs
were also isolated from sunflower apoplastic fluids which demonstrated accumulation phospholipids involved in signaling during hormonal treatments suggesting that these may play a role in
intercommunication [57]. These three reports were the first to associate the plant vesicular body
excretion to that of mammalian exosomes in a defensive and intercommunicative role. Thus,
supporting that non-mammalian derived exosomes are present in nature and share similar functionality to that of the mammalian derived exosomes.
The discovery of PDEs led to further discussion if PDEs could be taken into by mammalian cells as a form of interspecies cellular communication. Reports have shown that plant
miRNA have been discovered in breast milk exosomes and miRNA from dietary plants can affect metabolism [58, 59]. The method of how these miRNAs are delivered could be through the
use of PDEs. Exosomes can safely shuttle nucleotides to a recipient cell by encasing them in the
lipid membrane to avoid serum nucleases. It is possible that the mammalian cells are interacting
with the PDEs thus receiving the miRNA cargo. To date, only 4 papers address this interspecies
communication which are primarily performed by Dr. Huang-Ge Zhang’s group at the University of Louisville. The first among these was reported for grapes. Ju et al reported that the grapes
contained PDEs and administration could stimulate stem cell proliferation and could protect mice
from dextran sulfate sodium (DSS) induced colitis [60]. This marked the first time that PDEs
were extracted from an edible plant. Wang et al isolated PDEs from grapefruit and reported that
intestinal macrophages selectively uptook the PDEs and presented significant inhibition of IL-6
and IL-1 during DSS induced colitis [61]. Mu et al. isolated from grapes, grapefruit, ginger, and
carrots and demonstrated that PDEs anti-inflammatory responses with gut host cells through the
stimulation of IL-10 and inhibition of HO-1 [62]. Lemon derived exosomes were isolated from
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lemon juice and has shown to stimulate TRAIL-induced apoptosis in vitro and suppress the
growth of a CML xenograft model [63]. These provided the first documented interspecies crosstalk through PDEs.
The interest in PDEs was expanded by the possibility of using PDEs as a delivery system
for therapeutics. This suggestion came because of the selective uptake reported for grape and
grapefruit. Designing liposomes from PDE lipids could be a potential nano-delivery system. One
such formulation was reported by the same group. Wang et al. assembled a liposome made from
grapefruit-derived lipids and demonstrated that delivery of chemotherapeutic drugs, DNA expression vectors, and siRNA could be delivered in vivo to mouse tumor models [64]. This essentially demonstrated that liposomes assembled from PDEs could be potentially used for therapeutics as well as offer a new strategy through modification for selective targeting. Another advantage for this strategy is that since the formulation is assembled through naturally derived lipids it is largely not cytotoxic. As a result, clinical trials are being performed on PDEs for the delivery of curcumin to normal and colon cancer tissue and preventative treatment of oral mucositis
associated with head and neck cancer treatment.
Table 1.1: Known plant derived exosomes reported from literature and their reported biological effect.
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CD98-integrin pathway
CD98 is a multifunctional protein that has been implicated in activating integrin 1 [65,
66]. It is suggested that CD98 activates integrin by increasing integrin affinity to other ligands
[67]. It was later found that the cytoplasmic domain and transmembrane domains of CD98hc
were necessary for integrin interaction [68, 69]. Cross-linking of CD98 demonstrated an integrinlike signaling promoting phosphatidylinositol 3 kinase activity involved in anchorage independent growth, and it was also found that functional integrin 1 was necessary for CD98 signaling to
phosphorylate focal adhesion kinase in demonstrating that integrin 1 was essential for this signaling process of CD98 [70]. Overexpression of CD98 alters the surface distribution of integrin
1 and demonstrate increased FAK and PI3K activity [71]. Interestingly, knockout of CD98
demonstrated that CD98 was not required for integrin expression, affinity, and adhesion; however, disruption caused defects in cell spreading and cell migration which demonstrated that
CD98 is necessary for efficient integrin 1 signaling [72, 73]. Null-CD98 cells also demonstrated suppressed Akt phosphorylation as a result from suppressed PI3K activation [72]. CD98
was found to interact with CD147 to induce integrin 1 function to promote cyclosporine B-induced cell adhesion and p44/p42 MAPK activation following PI3K activation [74]. Because
CD98 can be found to be upregulated in various carcinomas it has been suspected that this overexpression can activate the integrin 1 signal pathway to promote tumor growth and play a role
in tumorigenesis. Supporting this, mice with downregulated CD98 presented reduced tumor
growth as well as lower production of proinflammatory cytokines while the overexpression led
to increased tumor growth with more incidence and greater production of proinflammatory cytokines [75]. Suppression of CD98 also demonstrated reduction cell motility due to decreased integrin 1 signaling involving FAK, AKT, and ERK, and demonstrated a reduction in MMP2
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expression which in turn resulted in increased extracellular galectin-3 [76]. Suppression of CD98
in renal cancer cells demonstrated defective cell spreading, migration, and survival [77]. Suppressed expression of CD98 in skin squamous cell carcinoma (SCC) protect against Ras-driven
skin carcinogenesis, demonstrated less stiffness by tuning the integrin/ROCK/YAP/TAZ pathways, and tumor regression [78]. A study involving 80 patients with colorectal cancer (CRC)
showed that CD98, integrin 1, integrin 3, and FAK demonstrated gradual increase in expression and patients with liver metastases presented the highest expression of each suggesting that
there is a link between this expression pattern and liver metastases from CRC [79].
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2

ROLE OF CD98 IN LIVER DISEASE

CD98 is a multifunctional glycoprotein that is involved in various biological processes
such as amino acid transport, cell adhesion, diffusion, and proliferation. The role of CD98 in
liver disease has not thoroughly been examined and are limited reports in the literature. Among
these reports, direct association for CD98 in nonalcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) have been reported. Our lab has reported that targeting CD98 in high
fat diet mice reduced steatosis and inflammation in NAFLD. Other reports associate CD98 in
HCC due in part to the role of CD98 in activating integrin signaling. Herein, we present CD98
staining on liver biopsies from NAFLD, chronic active hepatitis, cirrhosis, and 3 stages of HCC
to demonstrate the upregulation of CD98 expression throughout liver disease progression. In addition, we analyze current literature to elucidate roles and potential roles of CD98 with each
stage of liver disease.
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CD98
CD98 is a multifunctional glycoprotein protein consisting of a heavy chain and several light
chains. CD98 has been implicated in a variety of biological functions such as cell fusion, differentiation, proliferation, adhesion, and migration [80, 81]. This large distribution of function is due to
the ability of CD98 to act as a ‘molecular facilitator’ for activating integrin 1 and 3 signaling
which suppression of CD98 led to impaired signaling and the of CD98 light chain functions for
amino acid transport [68, 82]. The cytoplasmic domain and transmembrane domains of CD98hc
are necessary for integrin interaction while the ectodomain is required for amino acid transport
with the light chain [68, 69]. Overexpression of CD98 alters the surface distribution of integrin β1
and demonstrates increased FAK and PI3K activity [71]. Interestingly, knockout of CD98 demonstrated that CD98 was not required for integrin expression, affinity, and adhesion; however, disruption caused defects in cell spreading and cell migration demonstrating that CD98 is necessary
for efficient integrin β1 signaling [72, 73]. CD98 was found to interact with CD147 to induce
integrin β1 function to promote cyclosporine B-induced cell adhesion and p44/p42 MAPK activation following PI3K activation [74]. Although CD98 has been studied in a variety of biological
processes, the role of CD98 in liver disease has not been extensively studied. Herein we will discuss the literature associated to the involvement and potential involvement of CD98 in liver disease.
CD98 immunohistostaining
Liver tissues were analyzed for CD98 expression through US Biomax inc (Rockville, MD,
USA) on liver tissue array LV1201 using CD98ab (Santa Cruz, Ref# sc-9160)
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CD98 role in nonalcoholic liver disease
Fatty liver disease can be categorized into two groups: Alcoholic Fatty Liver Disease
(AFLD) and Non-Alcoholic Fatty Liver Disease (NAFLD which are defined by steatosis as a result
of overconsumption of alcohol and fatty foods [3]. NAFLD is typically an asymptomatic disease
and is often reversible by lifestyle changes. NALFD has gained attention due to effects of the longterm pathogenesis of the disease in which unchecked inflammation and oxidative damage can lead
to the progression to more severe liver diseases such as fibrosis, cirrhosis, and HCC [83].
Patients with healthy livers (Figure 2-1) exhibit basal levels of CD98 expression when compared
to patients with fatty degeneration which exhibit upregulation of CD98 (Figure 2-2). One method
of CD98 involvement may stem from galectin-3. Galectin-3 has been shown to recognize surface
glycoprotein receptors such as CD98 to induce CD98 activation [84]. Knockout experiments of
galectin-3 have proposed 3 mechanisms as a consequence in the development of NAFLD: increased receptor for advanced glycation end products (RAGE) which promote inflammatory pathways, accumulation of advanced glycation end products (AGE), and increased expression of peroxisome proliferator-activated receptor  (PPAR ) [85].
Recently our lab has published a paper demonstrating that CD98 may function as a key actor/inducer in NAFLD [18]. Our study showed that downregulating CD98 expression via CD98 siRNAloaded nanoparticles reduced inflammation and steatosis in the liver. In addition, fibrotic markers
were seemingly attenuated. Taken together CD98 could represent a key therapeutic target for preventing the transition of NAFLD to the severe liver diseases. Our study was the first documented
to show CD98 is implicated in NAFLD. The importance of this study is to show that CD98 is
upregulated as early as NAFLD.
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Figure 2.1- Basal expression level of CD98 in al hepatic tissue.
CD98 expression assessed by immunohistochemistry staining from tissue samples. A) Female
age 18, B) Male age 40, C) Male age 47 (Santa Cruz, Ref# sc-9160)

Figure 2.2 - CD98 upregulation in liver tissue with fatty degeneration (steatosis).
CD98 expression assessed by immunohistochemistry staining from tissue samples. A) Male age
56, B) Male age 55, C) Female age 69 (Santa Cruz, Ref# sc-9160)
CD98 role in nonalcoholic steatohepatitis
Non-alcoholic steatohepatitis (NASH) is characterized as a condition in which the liver cells
have lobular inflammation in addition to steatosis and is grouped together with chronic active
hepatitis [86]. NASH is generally asymptomatic and is frequently diagnosed in patients with
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metabolic syndrome. CD98 was found to be overexpressed in liver tissue of patients suffering from
chronic active hepatitis (Figure 2-3). However, direct involvement of CD98 has not been reported.
One possible link for CD98 to the progression of NAFLD to NASH could be related with its role
for T cell activation. The current 2 hit model for NAFLD pathogenesis links the initial steatosis as
the initial hit then subsequent inflammation and oxidation damage for the second hit where T cells
play a role [87]. T cell activation during obesity seems to play a critical role in upregulating inflammatory cytokines, adiponectin, and lipogenic enzyme mRNA levels in the spleen and liver
[88]. In this study, Poggi et al. demonstrated that knockout and downregulation of CD28 seemingly
improved liver steatosis and decreased mRNA levels of CD98. It has been reported that interferon
 (INF-) is upregulated in NASH [89]. INF- has been shown to induce the expression of epithelial
CD98 which could possibly explain the observed expression levels [90]. Thus, CD98 upregulation
in NAFLD could promote the progression to NASH via a similar mechanism.
Galectin-3 knockout mice prevented the development of NASH by down regulation of CD36
involved in fatty acid translocation and removal of ALE/AGE (advanced lipoxidation endproduct/advanced glycation endproduct) accumulation by the liver which is involved in inflammation
[91]. Similarly, it was shown that using an inhibitor of galectin-3, GR-MD-02, prevented fat accumulation, inflammation, and fibrosis in mouse models of NASH due to decreased CD36 and
ALE/AGE expression [25]. Activation of CD98 by galectin-3 can create a feedback loop for the
PI3K activation which in turn produces IL-4 that stimulates galectin-3 that will give rise to macrophage activation that is involved in disease pathology [92]. It is possible for the increased CD98
expression levels can stimulate galectin-3 for NASH progression.
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Figure 2.3- CD98 upregulation in liver tissue with chronic active hepatitis.
CD98 expression assessed by immunohistochemistry staining from tissue samples. A) Female
age 58, B) Male age 49, C) Male age 36 (Santa Cruz, Ref# sc-9160)
CD98 role in liver fibrosis and cirrhosis
Liver fibrosis is a condition where there is an excessive accumulation of the extracellular
matrix proteins which can lead to development of fibrous scar tissue. Fibrosis in the liver can
progress in patients with either NAFLD or NASH albeit to a different degree [93]. CD98 expression levels could serve as the proinflammatory mediator for the persistent damage. Integrin v1
was reported to be a binder of TGF for latent TGF activation in tissue fibrosis [94]. Fibrotic
progression in the liver could be linked to the activation of integrin v1 via CD98. CD98’s role
in T cell activation in which the TGF activation could also play a profibrotic role [95]. Over
proliferation of hepatic stellate cells has been linked to fibrogenesis [96]. It is possible that the
CD98 levels may play a role in increasing the proliferation of the hepatic stellate cells via integrin
activation. The only direct link is our report which showed that fibrotic markers on the liver were
seemingly attenuated by downregulating CD98.
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Liver cirrhosis is a condition where there is liver dysfunction due to the accumulation of
liver damage often measured by excess scarring. Similarly, CD98 upregulation was observed in
patient liver tissues with cirrhosis (Figure 2-4). Like NASH and liver fibrosis, little is known about
the direct involvement of CD98 in cirrhosis. Galectin-3 can be detected in patients with cirrhosis
supporting that galectin-3 could play a role in the pathogenesis of NAFLD to more extreme liver
diseases [97]. CD98 activation through galectin-3 may be a possible link.

Figure 2.4 - CD98 upregulation in liver tissue with cirrhosis.
CD98 expression assessed by immunohistochemistry staining from tissue samples. A) Female
age 60, B) Female age 26, C) Male age 57 (Santa Cruz, Ref# sc-9160)
CD98 role in hepatocellular carcinoma
The CD98 heavy chain has been studied to be a key player in tumorigenesis due to its role
in activating integrin signaling to promote tumor progression via angiogenesis, invasiveness, and
proliferation in addition to promoting malignant transformation of cells [81, 98]. In prolific endothelial cells, CD98 was found to be overexpressed and targeting CD98hc led to decreased ECassisted tumor growth and angiogenesis [99]. Silencing of CD98hc also decreased malignant
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behavior and tumor growth in renal cell cancers via loss of downstream signaling due loss of FAK
phosphorylation [77]. Crosslinking of CD98 was reported to increase the surface expression and
clustering of integrin β1 as well as increase integrin-like signaling [100, 101]. CD98 was further
implicated in tumorigenesis via increased PI3K activity from downstream FAK phosphorylation
from CD98-integrin signaling [71]. CD98hc-CD147 complexes present poor overall survivability
in non-small lung cancer patients and knock down of CD98hc and CD147 by RNA silencing in
cells lead to decreased Akt activity [102]. CD98hc silencing impaired tumorigenicity of HeLa cells
via defects in galectin-3, β-catenin, and integrin signaling [76].
The CD98 light chains have also been implicated in tumor growth via activation of mTOR
and providing essential amino acids for the tumor [103]. Active LAT1 expression has been associated to transitional cell carcinoma progression in upper urinary tract and malignant pleural mesothelioma [104, 105]. Overexpression of LAT1 was also observed in primary and metastatic sites
of human neoplasms which correlated to the proliferation and angiogenesis [106]. LAT1 downregulation in tumor cells exhibited significant growth inhibition [107]. Considering the mechanisms of both the heavy chain and light chain, CD98 plays many roles in tumor behavior and
development.
Overexpression of CD98 can be observed in patients with stage I, II, III hepatocellular
carcinoma (Figure 2-5). CD98 expression significantly increases with the severity of HCC. CD147
can redistribute CD98 to activate integrin signaling as well as through the upregulation of MMP2/9
for galectin-3 activation of CD98 in HCC [108]. Intracellular domain of CD98 truncations of CD98
exhibited inhibitory effect on integrin activation to prevent malignant development in HCC [109].
Another report linked the LAT1 to aiding tumor associated gene-1, TA1, with tumor progression
in rat liver tumor cells [110]. LAT1 has been shown to promote tumor growth with CD98hc in rat
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liver tumors [111]. LAT1 was also reported to be a prognostic marker for patients with HCC [112].
It was also reported that LAT1 expression correlated with tumor size and stage [113]. In terms of
metastasis, CD98 and LAT1 expression was found to be upregulated in metastatic sites on the liver
in which LAT1 expression correlated to proliferation and angiogenesis [106]. Metastasis of the
liver by colorectal cancer promotes the expression of CD98, integrin 1/3, and Fak [114]. Thus,
CD98 plays a role in the tumorigenesis of HCC and metastasis of the liver.

Figure 2.5-CD98 upregulation in liver tissue with hepatocellular carcinoma.
CD98 expression assessed by immunohistochemistry staining from tissue samples. A) Male age
65, B) Female age 35 (top), Female age 55 (bottom), C) Male age 58 (top), Male age 41 (bottom)
(Santa Cruz, Ref# sc-9160)
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Conclusion
From what has been reported there is a clear gap in studies regarding CD98 involvement in
liver disease in NAFLD, NASH, fibrosis, and cirrhosis. Our data presented that upregulation of
CD98 occurred throughout the pathogenesis of NAFLD. Our report was the first to directly link
CD98 to NAFLD. In addition, CD98 has been reported to play a role in HCC via integrin signaling.
In our review, we identified potential areas for which CD98 could be involved with NASH, fibrosis, and cirrhosis which are summarized in Figure 2-6. Further study will be needed to understand
the underlying mechanism to explain the role of CD98 in NAFLD pathogenesis.

Figure 2.6 - Summarized areas CD98 involvement in liver disease

22
CD98 expression assessed by immunohistochemistry staining from tissue samples (from previous figures) and upregulation/activation are indicated by ↑ and normal levels are indicated by –
as defined by the review text.

23
3

CD98 siRNA-LOADED NANOPARTICLES DECREASE HEPATIC STEATOSIS IN
MICE
Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive lipid hepatic ac-

cumulation. Here, we investigated whether a reduction of CD98 expression mediated by CD98
siRNA-loaded nanoparticles (NPs) could attenuate liver disease markers in a mouse model of
NAFLD. NPs were generated using a double emulsion/solvent evaporation technique. Mice fed a
high fat diet for 8 weeks to induce fatty liver were treated with vein tail injections of CD98
siRNA-loaded NPs. In vitro, HepG2 treated with CD98 siRNA-loaded NPs showed significant
downregulation of CD98 leading to a significant decrease of major pro-inflammatory cytokines
and markers. In vivo, CD98 siRNA-loaded NPs strongly decreased all markers of NAFLD, including the blood levels of ALT and lipids accumulation, fibrosis evidence and pro-inflammatory cytokines. In conclusion, our results indicate that CD98 appears to function as a key actor/inducer in NAFLD, and that our NPs approach may offer a new targeted therapeutic for this
disease.
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Background
Non-alcoholic fatty liver disease (NAFLD) is highly correlated to obesity and insulin resistance. It is a major problem as many studies have strongly correlated NAFLD with non-alcoholic steatohepatitis (NASH) and its possible pathogenesis to more dramatic liver diseases [93,
115], such as cirrhosis and hepatocellular carcinoma (HCC). Thus, this “benign” liver-associated
disease has been increasingly studied in the past decade [93, 115, 116].
The liver contributes to multiple functions, including: carbohydrate metabolism, plasma
protein synthesis, digestion, the disposal of drugs, toxins and hormones, phagocytosis, and the
metabolism of lipids, proteins and amino acids [117]. Some of the major diseases of the liver
include fatty liver diseases (FLD), NASH, hepatitis B and C, fibrosis, cirrhosis, and HCC. FLD is
classified into two types: NAFLD and alcoholic fatty liver disease (AFLD). NAFLD, which is
very common in adults and children of Western society due to the common consumption of a high
fat diet, is defined as lipid accumulation which progressively leads to NASH and dramatically
increases the risks of cirrhosis, liver failure, and HCC. [1, 2]. The pathogenesis of NAFLD is
poorly understood, but the disease has been associated with a number of metabolic conditions
including: insulin resistance, lipidemia and hepatic fibrosis [3, 118]. Several theories have been
put forth to explain the development of NAFLD. The most prominent is the multi-hit hypothesis,
which states that NAFLD begins with insulin resistance, which leads to the oxidization of lipids
and the release free fatty acids. In the first hit, the free fatty acids are repacked as triglycerides,
which are stored in fat vacuoles in the liver, causing hepatic steatosis [3]. In the second hit, lipid
oxidation causes oxidative damage through the production of reactive oxygen species (ROS) and
inflammatory mediators, such as tumor necrosis factor α (TNF-α), IL-6, cyclooxygenase 2 (Cox-
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2) and interferon gamma (IFN-γ) [3]. This damage disrupts apoptosis and allows the hepatic steatosis to progress to NASH [3].
CD98 is a cell-surface amino-acid transporter formed by covalent linkage of the CD98
heavy chain (CD98hc) with several different light chains (CD98lc). In this study, we targeted
CD98 by siRNA strategy to reduce the CD98hc. The justification of our strategy is that CD98hc
has particularly the function of a β1-integrin regulator and can be modulated by IFN-γ [119, 120].
The glycoprotein-associated transporters are a novel class of amino acid transporters that have
gained recent research interest, not only in relation to transport, but regarding the CD98-linked
functions in cell activation, integrin signaling, cell fusion and malignant transformation [121, 122].
In the context of intestinal inflammation, multiples studies have shown that pro-inflammatory cytokines upregulate CD98 expression, and that CD98 is a pro-inflammatory receptor involved in
many inflammation-related diseases and cancers of various organs, including the intestinal tract
[123-126] and lungs [127, 128]. Thus, blocking the progression of CD98 liver expression at an
early stage of the disease inflammation could represent a key therapeutic strategy for attenuating
the transition of NAFLD to cirrhosis or HCC.
CD98 has not been extensively studied in the liver, except in the context of HCC [110].
The significance of our study is to show that modulation of hepatic CD98 expression could represent a promising therapeutic strategy for treating and preventing hepatic diseases, such as NAFLD.
To test this hypothesis, we first tested CD98 siRNA-loaded NPs on HepG2 cells and generated a
mouse model of liver inflammation using a high-fat diet. Then, we treated the mice with CD98
siRNA-loaded NPs to decrease the liver CD98 expression.
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Methods
3.2.1

Preparation of CD98 siRNA/PEI-loaded NPs covered with PVA

NPs were synthesized via double emulsion/solvent evaporation, as described previously
[129]. An internal phase (see details below) containing the drug was mixed with 20 g/L of polylactic acid (PLA) in dichloromethane to generate a water-in-oil (W/O) emulsion after 2 min of
vertexing (Maxi Mix II, Thermodyne, Dubuque, Iowa) and 1 min of sonication with 50% active
cycles at 70% power (Pmax=400 W) (Digital Sonifier 450, Branson, Danbury, CT). This first emulsion was dropped in a second water phase containing 0.3g/L of PVA to generate a water/oil/water
emulsion (W/O/W).
The W/O/W emulsion was dropped in a dispersing phase of 0.1g/L polyvinylic alcohol
(PVA), and stirred at 45ºC under a vacuum to remove dichloromethane. NPs were centrifuged at
9953g and freeze-dried overnight at -50ºC under 0.1 mbar pressure. As the second emulsion allowed PVA to be grafted on the surface by hydrophobic interaction with the PLA matrix, NPs
were coated with PVA to prevent aggregations through electrostatic repulsions.
3.2.2

Preparation of the internal phase

The internal phase has a typical N/P ratio of the number of negative charges of siRNA
(CD98 siRNA or FITC-CD98 siRNA or scrambled siRNA) (P as the phosphorous charge) and
positive charges of PEI (N as the ammonium charge) (N/P ratios of 30 for PEI/siRNA). A mixture
of siRNA/PEI: 29 µL CD98 siRNA (5 µM) was combined with 18 µL PEI (5mM), and incubated
for 10 min at room temperature for complexation. After 10 min, a polyplex was formed, and 750
µL bovine serum albumin (BSA, 50g/L) added, generating the first emulsion with dichloromethane.
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3.2.3

Analysis of human samples biopsies stained for CD98

Human samples were obtained through US Biomax Inc. (Rockville, MD) with a declaration
of specimen collection stated as following: “Each specimen collected from any clinic was consented to by both hospital and individual. Discrete legal consent form was obtained and the rights
to hold research uses for any purpose or further commercialized uses were waived”.
Collection and preparation of human samples were done by the company US Biomax Inc.
(Rockville, MD) as described in the following (http://www.biomax.us/support.php). Briefly, each
single tissue spot on every array slide is individually examined by pathologists certified according
to WHO published standardizations of diagnosis, classification and pathological grade. Before the
tissue array are delivered to clients, standard immunohistochemistry tests are also performed to
ensure the accuracy and specificity of tissue array products. Neutral formalin-fixation and paraffinembedding procedures have been applied to all specimens obtained from clinics. Consequently,
no living organism would exist on any paraffin-embedded arrays. Staining has been performed
using classic immunohistochemistry technique for CD-98 (Santa Cruz, sc-9160, Dallas, TX).
3.2.4

SEM

NPs specimens were applied to glass coverslips, air dried and sputter coated with Au/Pd
using a Denton desktop sputter coater (Moorestown, NJ). The microscope used to take the picture
was a LEO 1450VP (New York, NY).
3.2.5

AFM Measurement

For atomic force microscopy (AFM) test, a drop of NPs made of PLA suspension was
deposited onto a freshly cleaved mica slide, followed by drying overnight at 25ºC. The images
were taken using a SPA 400 AFM (Seiko instruments Inc., Japan) at tapping mode using high
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resonant frequency (F0 = 150 kHz) pyramidal cantilevers with silicon probes at a scan frequency
of 1 Hz.
3.2.6

NPs size and zeta potential measurements

Diameters (nm) and zeta potential (mV) of NPs were measured by light scattering using 90
Plus/BI-MAS (multi-angle particle sizing) or light scattering after applying an electric field using
a ZetaPlus (zeta potential analyzer, Brookhaven Instruments Corporation, Holtsville, NY). The
average and standard deviations of the diameters (nm) or zeta potential (mV) were calculated using
3 runs. Each run is an average of 10 measurements.
3.2.7

WST-1

To assess the potential toxicity of CD98 siRNA/PEI NPs, a WST-1 assay was performed.
As described previously [130], cells were seeded in 96-well plates at a density of 5 × 104 cells per
well and exposed to 1 mg/mL of loaded NPs with or without CD98 siRNA/PEI for 48h. The WST1 assay measures cleavage of the soluble red tetrazolium salt, WST-1 (4-[3-(4-iodophenyl)-2-(4nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate), by dehydrogenase present in intact mitochondria, which leads to the formation of dark red formazan crystals. WST-1 proliferation reagent
(10 μL) was added to Caco2-BBE cells (10 μL/well) and incubated for 1–2 h at 37 °C. The wavelength for measuring absorbance of the formazan product was 440 nm.
3.2.8

Cell Culture and Lipopolysaccharides (LPS) induction

HepG2 cells, Caco2–BBe cells and RAW 264.7 cells were cultured to confluence in 75cm2 flasks at 37 °C in a humidified atmosphere containing 5% (v/v) CO2. The culture medium
was DMEM/Ham's F-12 medium (Invitrogen, Grand Island, NY) supplemented with l-glutamine
(2 mm), penicillin (100 units/ml), streptomycin (100 μg/ml), and heat-inactivated fetal calf serum
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(10%, v/v) (Atlanta Biologicals, Atlanta, GA). Lipopolysaccharides (LPS) was obtained from Salmonella enterica serotype enteritidis (L7770, Sigma-Aldrich, St Louis, MI). The stimulation of
cells was performed supplementing culture medium with 10µg/mL of LPS during 24h.
3.2.9

Intracellular NP uptake visualization

Confocal microscopy was employed to visualize the intracellular uptake of NPs (Zeiss
LSM510 Meta Confocal).
In vitro, HepG2 cells were seeded in four-chamber tissue culture glass slides (BD Falcon,
Bedford, MA, USA). For optimal visualization of siRNA uptake, 200µg/mL of FITC siRNAloaded NPs were exposed to cells overnight. Next, cells were washed 3 times with medium and 3
times with PBS to remove extracellular NPs, and subsequently fixed for 20 min in 4% paraformaldehyde. The fluorescent signal of NPs were visualized as bright light signal on the pictures in
gray scale color.
In vivo, after intravenous injection of FITC tagged siRNA loaded NPs (green), mice were
sacrificed 4 h later and liver samples were collected, Alexa Fluor 568 phalloidin (red) and DAPI
(purple) were successively added, and diluted 60 and 10,000 times for staining liver, kidney and
spleen tissues slides for 45 min and 5 min, respectively. To obtain comparable data, all photomultipliers used were adjusted to the same sensitivity (gain/offset).
3.2.10 Mice

All the mice experiments were approved by Georgia State University Institutional Animal
Care and Use Committee under protocol number A13041.

C57BL/6 female mice (8 weeks of age, The Jackson Laboratory) were used in the animal
experiments. Mice were group housed (25 °C), photoperiod (12:12-h light-dark cycle), and
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allowed unrestricted access to potables and standard mouse chow. C57BL/6 mice were fed a 60%
fat diet (Research Diets, Inc, D12492, New Brunswick, NJ) and a 10% fat control diet (Research
Diets, Inc, D12450B, New Brunswick, NJ) for a period of 8 weeks. Mice were injected twice
weekly via tail vein with CD98 siRNA-loaded NPs and scrambled siRNA loaded NPs.
3.2.11 Oil red (or Lipid vacuoles) staining and Hematoxylin and Eosin Y and red Sirius Staining Protocol
Oil red: A stock solution of Oil Red O must be prepared first by weighing out 0.5g of Oil
Red O (CAS#1320-065, Phaltz-Bauer, Waterbury, CT, 06708) and dissolving that in 100.0mL of
100% isopropanol. The tissue slides are washed for 10 minutes under running tap water. Slides are
then rinsed with 60% isopropanol before being placed in container with Oil Red O working solution for 15 minutes. The nuclei on the slides are then stained with Hematoxylin 2 (ThermoScientific, Kalamazoo, MI), by dipping the slides into the Hematoxylin solution 5 times. The slides are
then rinsed with H2O and allowed to air dry. To mount the slides, a drop of Cytoseal XYL (ThermoScientific, Kalamazoo, MI) is placed on the tissue and clear nail polish was used as a glue, to
place the cover slides.
Hematoxylin and Eosin Y: As tissues are embedded in paraffin, a dewaxing phase is
needed. The dewaxing phase consists of two 10 minutes washes with xylene, followed by two
washes with 100% ethanol for one minute, two washes with 95% ethanol for one minute, and two
washes with 75% ethanol for one minute. The slides are then stained with Mayer’s Hematoxylin
(Lillie’s Modification) (HMM500, Scytek, Logan, Utah) for 5 minutes. Slides are then washed
with DIH2O to remove excess stain. Bluing Reagent (BRT500, Scytek, Logan, Utah) for 10-15
seconds to enhance color of nuclei. A second rinse with H2O is performed followed by dipping the
tissues in 100% ethanol. The excess ethanol and stain are blotted off before staining with Eosin Y
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Solution (Modified Alcoholic) (Scytek, EYB500, Logan, Utah) for 2-3 minutes. The slides are
then rinse with 100% ethanol and allowed to air dry before mounting with Cytoseal XYL (ThermoScientific, 8312-4, Kalamazoo, MI, 49008). Cover slide is place over tissues with aid of clear
nail polish as glue.
The H&E stains were scored using the method developed by Kleiner et al [131] which
assigns score to 3 groups: steatosis, lobular inflammation, and hepatocyte ballooning. Steatosis
was score from 0-3, lobular inflammation was scored from 0-3, and hepatocyte ballooning was
scored from 0-2. The total score was added from the groups to yield a NAFLD activity score
(NAS).
3.2.12 RT-qPCR
Total RNA was extracted from Caco2-BBE, Raw 264.7 and HepG2 cells (in vitro) using
RNeasy Plus Mini Kit (Qiagen, Valencia, USA) according to the manufacturer’s instructions.
Yield and quality of RNA were verified with a Synergy H1 plate reader (BioTek, Winooski, USA).
cDNA was generated from the total RNAs isolated above using the Maxima first strand cDNA
synthesis kit (Fermentas, Glen Burnie, USA) according to the manufacturer’s instructions. Expression of the total RNA was quantified by RT-qPCR using Maxima SYBR green/Rox (6-carboxylX-rhodamine) quantitative PCR Master Mix (Fermentas, Glen Burnie, USA). The m36B4 was
used as a housekeeping gene in RT-qPCR. The data was analyzed using threshold cycle (CT)
method following ΔΔC=(CTtarget-CTHousekeeping)Group1 –(CTtarget-THousekeeping)Group2. The data
was derived from 2-ΔΔCT method. Sequences of all the primers used in RT-qPCR are m36B4 (forward 5'-TCC AGG CTT TGG GCA TCA-3’ and reverse 5’-CTT TAT CAG CTG CAC ATC ACT
CAG A-3’), mTNF-α (forward 5’-AGG CTG CCC CGACTA CGT-3’ and reverse 5’-GAC TTT
CTC CTG GTA TGA GAT AGC AAA-3’), mIFN-γ (forward 5’-CAG CAA CAG CAA GGC
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GAA A-3’ and reverse 5’-CTG GAC CTG TGG GTT GTT GAC-3’), mIL-1 beta (forward 5’TCG CTC AGG GTC ACA AGA AA-3’ and reverse 5’-CAT CAG AGG CAA GGA GGA AAA
C-3’), mCD98 (forward 5′-GAGGACAGGCTTTTGATTGC-3′and reverse 5′-ATTCAGTCGCTCCCCAGTG-3′, mCOX-2 forward 5’-TACCAGTCTCTCAATGAGTACC-3’ and reverse 5’-TGGTAGGCTGTGGATCTTGCACATTG-3’. Statistics for RT-qPCR was run by Prism
Graph Pad with the significance at p<0.05 with two-way ANOVA test.
3.2.13 Western Blot of Liver Samples
Liver tissue samples from mice receiving either fat diet with injection twice a week of
siRNA CD98 NPs or scrambled siRNA NPs, and mice on regular diet with injection twice a week
of scrambled siRNA NPs were homogenized with RIPA buffer (150 mM NaCl, 1.0% Triton X100, 0.5% Sodium deoxycholate, 0.1% SDS, 50mM Tris pH. 8.0, Roche phoSTOP and EDTAfree protease tablets). Concentrations of samples were measured using a DC assay (BIO-RAD,
Hercules, CA) on a Synergy H1 microplate reader (BioTek, Winooski, VT). Samples were prepared for equal loading at 100 µg for 12% SDS-PAGE. Primary antibodies (Abs) were incubated
with the membranes 2h at ambient temperature. The antibody loading was 1:1000 NFkβ (Santa
Cruz,sc-9160, Dallas, TX) and TGF β RII (Santa Cruz,sc-28975, Dallas, TX), GAPDH (Millipore,
AB2302, Temecula, CA) ), and CD-98 (Santa Cruz, sc-9160, Dallas, TX). The membranes were
washed with washing buffer. The membranes were incubated with secondary antibody, anti-rabbit
HRP conjugated (1:4000), for 1h 30 min at ambient temperature. The films were developed using
a SERIES 2000A Processor film developer. Membranes were recovered with RestoreTM Western
Blot Stripping Buffer protocol prior to additional incubations to other Abs.
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3.2.14 Elisa for secreted cytokines on HepG2 cells
HepG2 cells were grown in a 24 well plate then treated with CD98 siRNA-loaded NPs for
a period of 12h. Cells were then supplemented with 10 µg/mL LPS for a period of 24h. The supernatant was collected for the ELISA. Human TNF-α ELISA kit (ThermoScientific, EH3TNFA,
Kalamazoo, MI), Human IL-6 ELISA kit (ThermoScientific, EH2IL6, Kalamazoo, MI), and Human IFN-γ kit (ThermoScientific, EHIFNG, Kalamazoo, MI) were used to measure the levels of
secreted cytokines using the manufacturer’s protocols.
3.2.15 Flow cytometry
Isolation of total colonic cells for flow cytometry analysis.
Isolation of liver cells was performed. Briefly, liver was perfused with HBSS with 5% FBS
and 2 mmol/L EDTA at 37°C to remove blood. Large piece of liver were excised and cut longitudinally, washed of blood contents, cut into pieces 0.5 cm in length, and subjected to two sequential
20-minute incubations in HBSS with 5% FBS and 2 mmol/L EDTA at 37°C with agitation. After
each incubation step, media containing debris was discarded. The remaining tissue was minced
and incubated for 11 minutes in HBSS with 5% FBS, 1.5 mg/mL collagenase VIII (Sigma-Aldrich), and 40 U/ml DNase I (Roche Diagnostics, Indianapolis, IN) at 37°C in agitation. Cell suspensions were collected and passed through a 100-μm strainer and pelleted by centrifugation at
300 g. To perform flow cytometry analysis, the Abs below were used. Total liver cells were resuspended in phosphate-buffered saline (PBS) containing 5% fetal bovine serum (FBS). Live and
dead cells were determined by using the fixable Aqua Live/Dead cell staining kit (Invitrogen
Thermo Fisher Scientific, Waltham, MA) according to the manufacturer’s protocol. Cells were
stained at 4oC for 30 minutes with fluorescence-labeled Abs. After incubation, samples then were
washed 3 times in PBS containing 5% FBS and then cell were fixed/ permeabilized by
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fixation/permeabilization kit (eBioscience). Afterward, cells were incubated at 4oC with anti-Albumin and anti-HNF4α for 30 minutes followed by stain with PE- and PerCP-Cy5.5-linked secondary antibody, respectively. Flow cytometric analysis was performed with LSR II (BD Biosciences).
Flow cytometry analysis. Antibodies and reagents.
The following Abs were used: from eBioscience were CD11b (M1/70), CD11c (N418),
F4/80 (BM8). Abs purchased from BD Biosciences was HNF4α (MP6-XT22). Abs purchased
from Abcam was Albumin (ab19196). Abs 2.4G2 anti-FcγIII/II (BD Pharmingen) was used for
blocking of non-specific epitopes. Dead cells were identified using the fixable Aqua Dead Cell
Staining Kit (Invitrogen).
3.2.16 Statistical analysis
Statistical analysis was performed using unpaired two-tailed Student's t-test by InStat v3.06
(GraphPad) software. Values were expressed as means ± SE or means ± SD from experiments
performed in triplicate (n = 3), except for cytotoxicity tests and in vivo experiments (respectively
n = 8 and n=5). Data are representative of n determinations. ***P < 0.001, **P < 0.01, *P < 0.05
and NS, not statically significant.

Results
3.3.1

Hepatic CD98 is overexpressed in human liver biopsies from NAFLD patients

In tissue samples from humans of various ages, genders and liver pathologies, CD98 expression was assessed by immunohistochemistry staining. Figure 3-1 represented two selected and
significant examples of CD98 staining on human liver biopsies: a healthy 56-year-old man (Figure
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3-1A) and a 58-year-old man with nonalcoholic fatty liver (Figure 3-1B). Compared to the basal
expression of CD98 (brown staining obtained by classic immunohistochemistry staining) in the
healthy liver tissue sample (Figure 3-1A), the CD98 levels were significantly increased in the
NAFLD patient. Pathological analysis of the liver tissues from NAFLD patients also showed major
immune cells infiltration (circles on Figure 3-1B). Interestingly, we observed overexpression of
CD98 (brown staining) in membrane surfaces of both hepatocytes and immune cells. Based on this
extensive observation, we hypothesized that the downregulation of hepatic CD98 could dramatically counter the pro-inflammation caused by NALFD in the liver. This data demonstrates the
potential of CD98, not only as a marker of liver disease severity, but also as a potential therapeutic
target for the treatment of liver disease.

Figure 3.1:Signicance of Liver CD98 study based the symmetric evolution of the liver expression of CD98 with the severity of the nonalcoholic fatty liver disease in human patients.
The CD98 expression levels in human patient liver sample is dramatically overexpressed during
hepatic steatosis compared to healthy tissue. Human CD98 expression was visualized on a healthy
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56 years old man (A), a 46 years old man chronic active hepatitis with fatty degeneration of hepatocyte (B). (Santa Cruz, Ref# sc-9160)
3.3.2

Synthesis and characterization of CD98 siRNA-loaded polylactic acid (PLA)
NPs

CD98 siRNA-loaded NPs were successfully synthesized using our previously described
method [123, 132-137] (Scheme 2). In short, double emulsion/evaporation of organic solvent was
used to encapsulate the CD98 siRNA inside PLA matrix-based NPs. To ensure that the siRNAs
would be released in the cytosol (a prerequisite for CD98 knockdown), we electrostatically precomplexed the CD98 siRNA with a short-chain polyethylenimine (PEI). This should disrupt the
endosomal membrane according to the principle of the proton-sponge effect and extend the duration over which the siRNA is released [123, 134, 137].

Scheme 2: Polymer nanoparticle synthesis steps
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Using scanning electron microscopy, the NPs were estimated at 275 nm in diameter and
showed a homogeneous distribution (Figure 3-2A). This result was confirmed using atomic force
microscopy, which showed a homogenous distribution centered on a diameter of 280 nm (Figure
3-2B).
PEI/siRNA complex insured a “long lasting release profile” of the CD98 siRNA from the
NPs (Figure 3-2C). In Figure 3-2C, the “burst effect” (early and significant release of a drug from
drug-loaded NPs) [123, 134, 137] was not seen in our system: 60-70% of the active principle
remained inside the NPs after a 4-h incubation in PBS (Figure 3-2C). This laps of time is relatively
large for liver cells to take up the NPs from the blood stream (shown later in the study). Finally,
we used dynamic light scattering to further confirm the size of the NPs and assess their surface
charge. The diameter was confirmed to be around 275 nm, and the charge of the siRNA-loaded
NPs was around -12.84 mV (Figure 3-2D). This charge was consistent to insure optimal interactions with cell membranes, and the absolute value of the charge was enough to prevent NPs from
agglomerating via electrostatic repulsions [138]. As shown in Figure 3-2E, we studied the cytotoxicity of the CD98 siRNA-loaded NPs on HepG2 cell monolayers, and found that treatment of
cells with 1 mg/mL of the NPs for 72 h did not have any cytotoxic effect in this system (98.56%
viable cells). Similar results were obtained in Caco2-BBE and RAW 264.7 cells [123, 139-143].

38

Figure 3.2: The physicochemical properties of CD98 siRNA-loaded nanoparticles
(NPs).
(A) Scanning electronic microscopy image of 500 μg/mL CD98 siRNA-loaded NPs suspension.
(B) Atomic force microscopy image of 500 μg/mL CD98 siRNA-loaded NPs suspension. (C) Kinetic of release of CD98 siRNA complexed with PEI and loaded in NPs (PBS buffer, 37 oC) (D)
Size distribution and zeta potential (mV) measured by light scattering analysis of CD98 siRNAloaded NPs and scrambled siRNA-loaded NPs (values represent means ± SE. Data are representative of n=3 determinations). (E) Cytotoxicity of 1mg/mL CD98 siRNA-loaded NPs and scrambled
siRNA-loaded NPs on HepG2 cells for 72h (values represent means ± SE. Data are representative
of n=8 determinations).
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3.3.3

CD98 siRNA-loaded NPs were significantly uptaken by HepG2, Caco2-BBE,
and Raw 264.7 cells, and CD98 knockdown attenuated mRNA expressions of
major pro-inflammatory markers

The in vitro uptake of NPs by cells is a critical parameter in testing the efficiency of a
potential therapeutic vector. FITC-tagged CD98 siRNA-loaded NPs were significantly uptaken by
a monolayer of HepG2 cells (Figure 3-3A). The bright signal associated with the FITC-tagged
siRNA was significantly observed both at the membrane (early stage of endocytosis) and in the
cytosol (late stage of endocytosis). Furthermore, the integrity and intracellular efficiency of the
CD98 siRNA encapsulated in NPs was demonstrated measuring the expression level of CD98 by
quantitative real time polymerase chain reaction (qRT-PCR). The uptake of CD98 siRNA-loaded
NPs by cells (Caco2-BBE, RAW 264.7 and HepG2 cells) was also examined after lipopolysaccharide (LPS) stimulation in vitro. LPS stimulation (10 µg/mL LPS for a period of 24h) was found to
increase CD98 mRNA expression level compared to non-stimulated cells measured by qRT-PCR
(Figure 3-3B). Pretreatment of cells with CD98 siRNA-loaded NPs significantly downregulated
the LPS-mediated induction of CD98 by 7- (Raw 264.7), 6- (HepG2), and 8- (Caco2-BBE) times
compared to cells that were treated with control scrambled siRNA-loaded prior to LPS stimulation.
Pretreatment with CD98 siRNA-loaded NPs also decreased the LPS-mediated upregulation of proinflammatory markers, including IL1-β (7-fold for Raw 264.7 cells, 6-fold for HepG2 cells, and
10-fold for Caco2-BBE cells; Figure 3-3C), IFN-γ (10-fold, 6-fold, and 2-fold, respectively; Figure
2D), Cox-2 (5-fold, 4-fold, and 5-fold, respectively; Figure 3-3E), and TNF-α (90-fold, 10-fold
and 10-fold, respectively; Figure 3-3F).
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Collectively, our in vitro experiments showed that the CD98 siRNA-loaded NPs could efficiently downregulate CD98 and key regulators of inflammation. Therefore, we next tested these
NPs in the high fat diet-induced mouse model of NAFLD.

Figure 3.3: FITC-tagged siRNA/PEI-loaded NPs covered with PLA are rapidly
taken up by hepatic cells (HepG2 cells) and the CD98 siRNA is successfully delivered to the cytosol.
(A) Fluorescent microcopy of FITC-tagged siRNA/PEI-loaded NPs (200µg/mL, 100µL) uptaken
by HepG2 cells after overnight contact NPs/ HepG2 cells (gray scale picture). (B) Level of CD98
mRNA expression in non-stimulated HepG2 cells (control) or LPS-stimulated (10 µg/mL LPS for
a period of 24h) pretreated overnight with CD98 siRNA-loaded NPs (200µg/mL, 100µL)
(+LPS+CD98 si NPs) and scrambled siRNA loaded NPs (200µg/mL, 100µL) (+LPS-CD98 si
NPs). (C) Level of IL1-β mRNA expression in non-stimulated HepG2 cells (control) or LPS-stimulated pretreated overnight with CD98 siRNA-loaded NPs (200µg/mL, 100µL) (+LPS+CD98 si
NPs) and scrambled siRNA loaded NPs (200µg/mL, 100µL) (+LPS-CD98 si NPs). (D) Level of
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IFN-γ mRNA expression in non-stimulated HepG2 cells (control) or LPS-stimulated pretreated
pretreated overnight with CD98 siRNA-loaded NPs (200µg/mL, 100µL) (+LPS+CD98 si NPs)
and scrambled siRNA loaded NPs (200µg/mL, 100µL) (+LPS-CD98 si NPs). (E) Level of Cox-2
mRNA expression in non-stimulated HepG2 cells (control) or LPS-stimulated pretreated overnight
with CD98 siRNA-loaded NPs (200µg/mL, 100µL) (+LPS+CD98 si NPs) and scrambled siRNA
loaded NPs (200µg/mL, 100µL) (+LPS-CD98 si NPs). (F) Level of TNF-α mRNA expression in
non-stimulated HepG2 cells (control) or LPS-stimulated pretreated overnight with CD98 siRNAloaded NPs (200µg/mL, 100µL) (+LPS+CD98 si NPs) and scrambled siRNA loaded NPs
(200µg/mL, 100µL) (+LPS-CD98 si NPs). Values represent means ± SE. Data are representative
of n=3 determinations. ***P < 0.001, **P < 0.01, *P < 0.05 and NS, not statically significant.
3.3.4

CD98 siRNA-loaded NPs significantly reduced the secreted protein expressions
of TNF-, IL-6, and INF- on HepG2 cells stimulated by LPS

The reduction of major pro-inflammatory player shown by mRNA quantification (Figure
3-3 B-F) was confirmed by secreted protein quantification of TNF-α, IL-6 and IFN-γ (Figure 3-4).
Based on ELISA quantification, Figure 3-4 showed, respectively, the reduction of secretion of
TNF-α by 14% (Figure 3-4A), IL-6 by 6% (Figure 3-4B) and IFN-γ by 500% (Figure 3-4C). Altogether, the results based on cells shown in Figure 3-3A-F and Figure 3-4A-C demonstrated that
CD98 siRNA loaded NPs were effectively uptaken and the siRNA was released inside cells. This
cytosolic release led to a reduction of all major pro-inflammatory signals via CD98 knockdown
strategy. Based on those results, we transposed the study in vivo treating mice with CD98 siRNA
loaded NPs simultaneously with high fat diet inducing NAFLD.
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Figure 3.4: CD98 siRNA-loaded NPs significantly reduced the secreted protein expressions of TNF-α, IL-6 and IFN-γ on HepG2 cells stimulated by LPS.
HepG2 cells were treated with siRNA CD98-loaded NPs (200 µg/mL, 100 µL) for 12h. Cells were
supplemented with 10 µg/mL LPS for a period of 24h. The data presented the relative fold change
of secreted proteins as compared to the corresponding control set at the value 1. A) TNF-α, B) IL6, C) IFN-γ. Values represent means ± SE. Data are representative of n=3 determinations. ***P <
0.001, *P < 0.05 and NS, not statically significant.
3.3.5

CD98 siRNA-loaded NPs were significantly uptaken by liver cells, where they
attenuated the disease markers of high fat diet-fed mice

Age-matched female C57BL/6 mice were fed a high fat diet for 8 weeks and treated with
twice-weekly intravenous injections of CD98 siRNA-loaded NPs (5mg/mL, 100µL) or scrambled siRNA-loaded NPs (5mg/mL, 100µL)). Fluorescent staining of nuclei (DAPI, blue), actin
(rhodamine phalloidin, red) and NPs (FITC, green) was assessed (Figure 3-5A and 3-5B). Normal patterns (without NPs cytotoxicity observed) were observed for liver samples obtained from
mice treated with the scrambled (non-fluorescent) siRNA (Figure 3-5A), whereas a significant
green signal (corresponding to the fluorescent-tagged siRNA) was observed in samples from
mice treated with the CD98 siRNA-loaded NPs (Figure 3-5B). Thus these NPs had significant
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uptake by liver cells. Next, we examined high fat diet-induced histological changes (i.e., accumulation of lipid vacuoles in the cytosol, fibrosis, etc.) in liver tissues from mice treated with the
scrambled siRNA-loaded NPs or CD98 siRNA-loaded NPs. Microscopic analyses of H&E and
Sirius red-stained liver sections from these mice revealed the presence of lipid vacuoles (hepatic
steatosis) and fibrotic tissue (yellow arrow) in livers from high fat diet-fed mice injected with
scrambled siRNA-loaded NPs (Figure 3-5C and 3-5D), but not CD98 siRNA-loaded NPs (Figure
3-4E and 3-4F). The NAFLD score and fibrosis score were determined using the method developed by Kleiner et al [131]. The NAFLD activity score was determined to be 7 for the scrambled
siRNA-loaded NP liver tissue, which demonstrated high levels of steatosis, lobular inflammation, and a few instances of hepatocyte ballooning (Figure 3-5G). The fibrosis stage was determined to be 1 for scrambled siRNA loaded NP liver tissue. In contrast, CD98 siRNA-loaded NP
liver tissue had a NAFLD score of 0 and no presence of fibrotic tissue.
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Figure 3.5: Mice treated with CD98 siRNA-loaded NPs (twice weekly by tail vein injection) show significant liver NP uptake and decreased lipid vacuolization when fed
a high fat diet for 8 weeks.
(A, B) Liver pictures of mice injected with scrambled siRNA loaded NPs (5mg/mL, 100µL) (A)
and FITC tagged siRNA-loaded NPs (5mg/mL, 100µL) (B). After intravenous injection of FITC
tagged siRNA-loaded NPs (5mg/mL, 100µL) (green), mice were sacrificed 4 h later and liver
samples were stained for Alexa Fluor 568 phalloidin (red) and DAPI (blue). Representative hematoxylin and eosin (D, F) and Sirius Red (C, E)-stained sections of liver from 8 weeks high far
diet fed mice receiving respectively scrambled siRNA-loaded NPs (5mg/mL, 100µL) (C, D) or
CD98 siRNA-loaded NPs (5mg/mL, 100µL) (E, F) for 12 weeks. Scale bar is 50 µm. n = 5 mice
per group. Hematoxylin and Eosin Y stained liver tissue was scored using the scoring system
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developed by Kleiner et al [131] of mice injected twice weekly with NP treatments (5mg/mL,
100µL) (G).
In terms of serum markers, high fat diet-fed mice injected with scrambled siRNA-loaded
NPs (similar to control mice) had significantly elevated serum levels of alanine aminotransferase
(ALT) (Figure 3-6A), liver triglycerides, cholesterol, high-density lipoprotein cholesterol
(HDLc) and glucose (Figure 3-6B). In contrast, the corresponding mice treated with CD98
siRNA-loaded NPs had normal serum ALT and liver triglyceride levels, which represented a
13.7% decrease in triglyceride and 6.7% decrease in HDLc levels compared to that of the scrambled siRNA-loaded NP (Figure 3-6A and 3-6B).
Together, these findings indicate that our passive NP-mediated targeting strategy (i.e.,
due to the ability of liver macrophages to trap particles from the bloodstream) significantly delivered the NPs and released the CD98 siRNA to the liver of mouse. Thus, we next continued examining the beneficial outcome of CD98 siRNA loaded NPs on reducing liver pro-inflammatory
response to high fat diet by measuring locally in the liver the expression of inflammation markers.
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Figure 3.6: CD98 siRNA-loaded NPs reduce the levels of pro-steatosis markers
(blood ALT and lipids) associated with the high fat diet fed mice.
(A) Serum ALT levels of mice maintained for 8 weeks on regular diet with injection of scrambled siRNA-loaded NPs (5mg/mL, 100µL) (regular diet + scrambled siRNA NP) or high fat diet
(8 weeks) with twice a week injections of CD98 siRNA NPs (5mg/mL, 100µL) (HFD + siRNA
CD98 NP) or scrambled siRNA-loaded NPs (5mg/mL, 100µL) (HFD + scrambled siRNA NP).
(B) Liver triglyceride, cholesterols, high density lipoprotein cholesterol (HDLc) and glucose levels of mice maintained for 8 weeks on regular diet with injection of scrambled siRNA-loaded
NPs (5mg/mL, 100µL) (regular diet + scrambled siRNA NP) or high fat diet (8 weeks) with
twice a week injections of CD98 siRNA –loaded NPs (5mg/mL, 100µL) (HFD + siRNA CD98
NP) or scrambled siRNA-loaded NPs (5mg/mL, 100µL) (HFD + scrambled siRNA NP). Values
represent means ± SE. Data are representative of n=5 mice per group. **P < 0.01, *P < 0.05 and
NS, not statically significant.
3.3.6

The protein expression levels of CD98 is downregulated in the livers of mice
treated with CD98 siRNA-loaded NPs

Based on our mRNA results, we next assessed the levels of relevant proteins in the liver.
Western blot analysis (Figure 3-7) showed that the livers of high fat diet-fed mice injected with
CD98 siRNA-loaded NPs had dramatically lower CD98 protein expression compared to mice
treated with scrambled siRNA-loaded NPs or control mice fed a regular diet. These results indicated that our NP-mediated delivery of CD98 siRNAs successfully downregulates CD98 expression in the liver. The decreased level of CD98 expression has beneficial impacts on liver inflammation in high fat diet-fed mice.
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Figure 3.7: CD98 siRNA-loaded NPs suppress the protein expression level of CD98
in mice with high fat diet-induced hepatic steatosis.
Assessment of CD98 in liver from n mice (n being the number of mice used for each group as
indicated by the different lines of the WB) fed with regular diet and injected twice a week with
scrambled siRNA loaded nanoparticles (5mg/mL, 100µL) (regular diet + scrambled siRNA NP)
or with high fat diet for 8 weeks and injected twine a week with CD98 siRNA loaded nanoparticles
(5mg/mL, 100µL) (HFD + siRNA CD98 NP) or scrambled siRNA loaded NP (5mg/mL, 100µL)
(HFD + scrambled siRNA NP) during 8 weeks. HFD + CD98 siRNA-NPs (n=5), HFD + scrambled
siRNA-NPs (n=5), and RD + scrambled siRNA-NPs (n=4). n represents the number of mice for
each group.
3.3.7

CD98 siRNA loaded NPs IV injections preferentially target the liver locally specifically release siRNA to hepatocytes and Kupffer cells

We explored the biodistribution of FITC tagged NPs on different mice organs; heart, lung,
brain, colon, kidney, spleen and liver were collected after 8 weeks of HFD and biweekly intravenous injections of NPs (1mg/mL, 100µL). Among all organs collected, only kidney, spleen and
liver showed a FITC signal shown in Figure 3-8. Using the Cellsens dimension fluorescence analysis software, we managed to get fluorescent pictures totally free of tissues autofluorescence signal
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by optimizing the pictures acquisition of control tissues not treated with FITC-loaded NPs from
kidney (Figure 3-8A), spleen (Figure 3-8B) and liver (Figure 3-8C). The fluorescent signal pictures
of kidney, spleen and liver showed respectively in Figure 3-8D, 8E and 8F only show the fluorescent due to FITC loaded NPs. As observed on Figure 3-8D, kidney had significant uptake of NPs
versus a light uptake which was observed for spleen (Figure 3-8E). Interestingly, mice livers significantly uptake FITC-loaded NPs as shown in Figure 3-8E, confirming more strongly that the
beneficial effect of CD98 loaded NPs on NAFLD was due to direct liver cells uptake.

Figure 3.8: Biodistribution study relative to liver, kidney, and spleen demonstrated
significant uptake of the siRNA FITC-loaded NP while mice received HFD.
Histology after tail veins intravenous injections of FITC tagged siRNA-loaded NPs (5mg/mL,
100µL) (green), mice were sacrificed and (A, D) kidney, (B, E) spleen, and (C, F) liver samples
were stained for Alexa Fluor 568 phalloidin (red) and DAPI (blue). Mice were fed a high fat diet
for 8 weeks along with biweekly tail vein intravenous injections of FITC-loaded NPs (5mg/mL,
100µL). Scale bar is 50 µm.
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Figure 3.9: Biodistribution study relative to liver, kidney, and spleen demonstrated
significant uptake of the siRNA FITC-loaded NP while mice received LFD.
Histology after tail veins intravenous injections of FITC tagged siRNA-loaded NPs (5mg/mL,
100µL) (green), mice were sacrificed and (A, D) kidney, (B, E) spleen, and (C, F) liver samples
were stained for Alexa Fluor 568 phalloidin (red) and DAPI (blue). Mice were fed a high fat diet
for 8 weeks along with biweekly tail vein intravenous injections of FITC-loaded NPs (5mg/mL,
100µL). Scale bar is 50 µm.

Complementing those observations, we studied the uptake of FITC loaded NPs during low
fat diet. After avoiding tissue auto-fluorescence, as previously mention (Figure 3-9A, 9B and 9C),
we noticed that kidney and spleen cells were not uptaking as much NPs as compared with HFD
(Figure 3-9D, 9E). Interestingly, liver cells had significant uptake of the FITC loaded NPs also
during low fat diet (Figure 3-9F).
Finally, we analyzed further the biodistribution at the cellular level within the liver using
flow cytometry analysis. Flow cytometry, noted in Figure 3-10A, 10B, 10C, and 10D, showed that
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CD98 siRNA loaded NPs mainly target hepatocytes (FITC+ albumin+, Figure 3-10D) and macrophages like cells (FITC+ CD11b+, Figure 3-10B), but not dendritic cells (FITC+ CD11c+, Figure
3-10C). We noticed that liver cells from mice suffering NAFLD were uptaking NPs differently
when healthy or receiving HFD. like cells and hepatocytes from HFD treated mice, had three times
more NPs uptake than cells in normal conditions respectively, 1.66 vs 5.32 (Figure 3-10B) and 6.7
vs 18.0 (Figure 3-10D). Dendritic cells were not significantly “stimulated” by HFD with very low
NPs uptake (below 1 for both conditions, Figure 3-10C). We also noticed that HFD induced cell
death rate in the liver decreased from 63.4 to 50.4 (Figure 3-10A).

Figure 3.10: Flow cytometry analysis indicating that biweekly injection of CD98 siRNAloaded NPs is significantly uptake by hepatocytes and macrophage-like cells compared to
dendritic cells.
Representative FACS plots illustrating the gating strategy utilized to define live cells (A),
macrophages like cells (B), dendritic cells (C) and hepatocytes (D) for mice biweekly injected with
FITC-loaded NPs (5mg/mL, 100µL) and receiving or not HFD. Cells were gated as followed for
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hepatocytes CD45-MHC class II- F4/80−CD11b-CD11c-albumin+, macrophages-like cells
CD45+MHC class II+F4/80+CD11b+CD11c- cells and dendritic cells CD45+MHC class II+
F4/80−CD11b+CD11c+. Values represent means ± SE. Data are representative of n=5 mice per
group. **P < 0.01, *P < 0.05 and NS, not statically significant.
Discussion
CD98 is a type II transmembrane protein that covalently links to one of several L-type
amino acid transporters (light chains) to form large, functionally heterodimeric neutral amino acid
transport systems [119, 120]. CD98 is constitutively expressed by a variety of tissues, including
the liver, which can express different L-type amino acid transporters, including LAT-1 (large neutral amino acid transporter, Na+-independent; fetal liver), y+-LAT-2 (cationic and large amino acid
transporter, Na+-independent; liver) and asc-1 (small amino acid transporter, Na+-independent;
liver) [144]. In addition to functioning as an amino acid transporter via its extracellular domain
[120, 145], CD98 also regulates cell homeostasis by modulating the activation of integrin [65, 125,
146-148]. Importantly, Yan et al. [149] demonstrated that DSS-induced colitis in mice (a colonic
inflammation model) altered the expression of epithelial CD98, which is mediated via interferongamma (IFN-γ). The authors further showed that CD98 expression is activated at the transcriptional level in IFN-γ-treated cells, and examined the related mechanisms in the colonic epithelium
[149]. IFN-γ is present at high levels in pathological liver tissues, including those from NAFLD
patients [150-153]. Similar to IFN-γ, the synthesis of cytokines, such as TNF-α and IL-6, both
involved in inflammatory and metabolic alterations, characterizes the earliest phases of different
liver injury, leading to the synthesis of other cytokines that, jointly, induce cell migration and
initiate healing processes, including fibrosis [154]. A correlation has been found between TNF-α
levels and fibrosis degree in NASH patients [155], as gene expression of either TNF-α or its
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receptor is significantly elevated in their hepatic and adipose tissues [156]. Similar correlation has
been found in NAFLD patients, whose circulating TNF-α were significantly elevated concomitantly with the increase in the activity score, NAS, the histologic scoring system recognized as
standard reference in the evaluation and gradation of hepatic inflammation and damage [157].
Also, progression of NAFLD correlates with polymorphisms in the TNF-α promoter region and
serum level of soluble TNF receptor 2 [158]. A previous study showed that antibody-based inhibition of TNF-α ameliorated the chronic stage of colitis (16). However, systemic antibody treatment is often associated with important side effects [159, 160]. Here, we show that targeted downregulation of CD98, specifically in the liver, can be achieved using siRNA-loaded NPs. In such
inflammatory context as described above, local damages (caused by overexpression of IFN-γ,
TNF-α and IL-6) on the epithelium of veins and arteries lead to a leakage [161-164]. NPs potentially used those defects to enter the space of Disse and interact directly with hepatocytes. Consequently, CD98 siRNA-loaded NPs were taken in by both macrophages-like cells and hepatocytes
to effectively downregulate CD98 expression at the mRNA and protein levels. This treatment dramatically decreased the progression and symptoms in a mouse model of NAFLD. The inflammation due to the accumulation of lipids in liver cells (inherent to the high fat diet) was significantly
decreased, as were the expression levels of all major inflammatory markers, including IFN-γ,
which is a direct modulator of CD98 [149].
In conclusion, we have shown that CD98 is more than a marker for liver injury; rather, it
should be considered a potential therapeutic target for NAFLD. In the future, we hope to improve
the utility of our CD98 siRNA-loaded NPs, in particular, by modifying the polymer matrix into a
stable bilayer liposome. This modification will allow us to anchor specific ligands on the liposome
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surface, thereby further increasing the ability of these NPs to target liver cells, and perhaps even a
specific cell type within the liver (i.e., hepatocytes, stellate cells, Kupffer cells, etc.).
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4

ROLE OF COLORECTAL CANCER-DERIVED EXOSOMES IN HEPATOCELLULAR CARCINOMA
The role of tumor derived exosomes has been questioned for aiding metastasis as some

tumor derived exosomes participate in developing cellular environments that support metastasis
in various organs. Patients suffering from colorectal cancer commonly develop liver metatstasis,
thus the role of exosomes from CRC could participate liver metastasis. Exosomes were extracted
and characterized from Caco2 BBe cells. The exosome uptake and surface protein distribution
were determined with fluorescent microscopy. The biological effects of uptake were determined
with qPCR, Elisa, and western blot. Exosomes from Caco2 BBe cells were extracted and the
cells exhibited high uptake of the exosomes with the HepG2 cells. The integrin signaling pathway was examined for HepG2 with the colorectal cancer derived exosomes Caco2 BBe. The results showed that treatment increased the expression of integrin 1, integrin 3, FAK, NFB,
PI3K 100, PI3K 100, p38 MAPK, and SAPK JNK and an increase in the secretion of inflammatory cytokines IL6 and TNF. In addition, the treatment of the Caco2 BBe exosomes induce a
membrane rearrangement that seems to support the increased integrin 1 clustering with CD98.
The results suggest that exosomes derived from Caco2 BBe can increase integrin signaling
which can contribute to metastasis or a more tumorigenic phenotype.
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Introduction
Colorectal cancer (CRC) is the 2nd most common cause for cancer death[165]. While the
occurrence of multiple primary cancers is relatively rare, there are reported cases of patients suffering from HCC and CRC [166]. The liver is also the most common area are for CRC metastasis. It has been reported that 20-35% of patients with advanced CRC will develop liver only metastasis [167]. One report showed that patients with liver metastasis have upregulated levels of
CD98, Integrin 1, Integrin , and FAK [79]. CD98 has been associated to biological functions
such as cell proliferation, adhesion, and migration which is linked to its ability for activating integrin 1 and integrin       Focal adhesion kinase (FAK) activation promotes cell motility, survival, and proliferations and can be found overexpressed in cancer [168].
It was also shown that FAK upregulation can ‘rescue’ integrin signaling in conditions where
CD98 expression is impaired [101].
Recently, exosomes derived from tumor cells has gained interest in developing ‘pre-metastatic niches’ on a tissue in order to progress into a metastatic transformation [169]. Exosomes
are nano-sized vesicular bodies that are secreted in cells. Their ability to be uptaken by a recipient cell demonstrated the possibility that tumor derived exosomes could possibly assist in transferring information for metastasis [170]. Pancreatic cancer derived exosomes, for example, have
been shown to be uptaken by Kupffer cells in an indirect relay of information to hepatic stellate
cells for the development of the pre-metastatic niche [171]. The idea that metastasis from various
cancer was associated to exosomes was further investigated with the proteome of tumor derived
exosomes contained unique integrin expression patterns which associated the exosome uptake
for a specific tissue for metastasis [172].
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CRC-derived exosomes were shown to play a role in tumor development in the liver via
the recruitment of CXCR4 expressing stroma cells to develop the pro-metastatic environment
[173]. In addition, this study demonstrated that colonization of Caco2 BBe cells was increased
with prior treatment of exosomes from the aggressive HT-29 colorectal cancer cell line. Exosomes derived from the colorectal cancer cell line SW480 were shown to promote cell migration
in HepG2 cells via the MAPK pathway [174]. These reports demonstrate that CRC-derived exosomes can induce a biological response in healthy and tumor hepatocytes. In this study, we further demonstrate that the role of colorectal cancer derived exosomes on liver cells may contribute
to the metastatic transformation and progression in liver disease via upregulation of the CD98Integrin signaling pathway.
Methods
4.2.1

Extraction of Exosomes from Caco2 BBe Cells

Caco2 BBe cells were grown to 80% confluence in Dulbecco’s Modification of Eagle’s
Medium, DMEM, with 1 g/L glucose L-glutamine & sodium pyruvate (Mediatech, Inc., Manassas, VA) in 175 cm 2 cell culture flasks (Denville Scientific Inc, Metuchem, NJ). The media was
exchanged for DMEM containing exosome depleted FBS. The media was collected every 2 days.
The collected media were centrifuged at 10,000 x g for 1 hour at 4oC to cell debris. The supernatant was vacuum filtered with a 0.22-micron filter flask to remove any residual low density solids. The samples were ultracentrifuged at 100,000 x g for 1-2 hours at 4oC. The pellets were
washed with sterile PBS and ultracentrifuged at 100,000 x g for 1 hour at 4oC. The pellet was resuspended in sterile PBS. The samples were then analyzed using a 90 Plus Particle Size Analyzer
(Brookhaven Instruments Corporation, Holtsville, USA) to determine the size and the charges.
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4.2.2

Physical Characterization of PDEs using Atomic Force Microscopy and Transmission Electron Microscopy

Atomic force microscopy (AFM) samples were prepared by placing a drop of 100 g/mL
exosomes onto mica slides for 30 min. The mica slides were washed with PBS and dried for 24
hours. The AFM samples were analyzed on a SPA 400 (Seiko instruments, Chiba, Japan) using
soft tapping mode.
The Caco2 BBe exosome pellets were resuspended in ddH2O to remove PBS salts. The
PDEs were fixed with glutaraldehyde containing 2.5% cacodylate buffer (0.1 mol/L, pH7) at
4oC. The samples were rehydrated with increasing alcohol concentrations of 30%, 50%, 70%,
90%, and 100% vol/vol for 2 min each. The samples were incubated with hexamethyldisilazine
for 5 min and dried under a ranged hood. The plots were fixed on an aluminum support with carbon-adhesive glue and coated with gold phaladium (Spotter Coater SC7640). The samples images were taken under transmission electron microscope (Cambridge Instruments Stereoscan S).
4.2.3

Cell Cytotoxicity Test

HepG2 cells were plated on in a flat bottom 96 well plate in DMEM media until >90%
confluence. The media was replaced with DMEM/F – 12 50/50 media with 100 g/mL of Caco2
BBe exosomes overnight. Then 10 L MTT reagent (Trevigen, Gathnerburg, MD) for 2 hours
followed by the addition of 100 L of the detergent (Trevigen, Gathnerburg, MD) for 4 hours.
The plate was read at 550 nm on a Synergy H1 Microplate reader (BioTek, Winooski, VI).
4.2.4

Microscopy: Exosome uptake and surface protein staining

Exosomes from Caco2 BBe was labeled using 1 mM coumarin-6 (Sigma-Aldrich, St
Louis, MO). Coumarin-6 based dyes are uptaken into membranes and are fixed on the bilayer
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[14]. Exosome (100 g) in were incubated with 1  C-6 for 30 min at ambient temperature.
The C-6-labelled exosomes were purified using an Exosome Spin Column (Life Technologies,
Green Island, NY) using the manufacturer’s protocol. HepG2 cells were grown on Lab-Tek II
CC2 Chamber Slides (Thermo Fisher Scientific Inc., Waltham, MA) until >90% confluence in
Dulbecco’s Modification of Eagle’s Medium, DMEM, with 1 g/L glucose L-glutamine & sodium
pyruvate (Mediatech, Inc., Manassas, VA). The media was changed to Dulbecco’s Modification
of Eagle’s Medium / Ham’s F-12 50/50 Mix, DMEM/F – 12 50/50 with L-glutamine & 15 mM
HEPES (Mediatech, Inc., Manassas, VA) and then supplemented with the C-6 labelled exosomes
for 24 hours. After incubation, the media was drained and the cells were washed with Dulbecco’s
Phosphate Buffered Saline, DPBS, with magnesium and calcium (Mediatech, Inc., Manassas,
VA). Cells were fixed 4% formaldehyde (Electron Microscope Sciences, Hatfield, PA) for 15
min. The cells were then incubated with 1:60 AlexaFluro 568 phalloidin (Life Technologies,
Carlsbad, USA) in DPBS 1 hour and fixed with Vecta Shield with DAPI (Vector Laboratories
Inc, Burlingame, USA). Slides were imaged on a Fluorescent microscope (Olympus, Shinjuku,
Tokyo). Cells were stained for CD98 with the C-6 labelled exosomes using the cross-staining
protocol described for the cross staining.
Cells were cultured similarly to the exosome uptake study for the surface staining. A 100
mM solution of palmitic acid stock was dissolved in 100 mM NaOH at 70oC. A 10% BSA solution was prepared in ddH2O at 55oC. The palmitic acid conjugated to BSA by preparing 10 mM
solution of PA with 1% BSA at 55oC for 30 minutes. The solution was cooled and filtered with a
.22-micron filter. Cells were supplemented with LPS, PA, and PA/LPS for a period of 24 hours.
Cells were then treated with unlabeled exosomes for 24 hours. After incubation, the media was
drained and the cells were washed with Dulbecco’s Phosphate Buffered Saline, DPBS, with
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magnesium and calcium and fixed with 4% formaldehyde for 15 min. Cells were washed with
DPBS then blocked with blocking buffer (1X PBS/5% BSA/0.3% Triton™ X-100) for 1 hour.
Cells were then incubated overnight at 4oC with two antibodies CD98/Integrin 1, and Fak/Integrin 1 antibodies in antibody dilution buffer (1X PBS/1% BSA/0.3% Triton™ X-100). The
cells were rinsed with DPBS and fluorescent tagged secondary antibody for 2 hours. The cells
were washed with DPBS 3 times then stained with DAPI for 10 mins. The slides were sealed
with Prolong® Gold Antifade Reagent. Slides were imaged on a Fluorescent microscope.
4.2.5

Flow cytometry: Exosome uptake determination after inflammation and steatosis on HepG2 cells

HepG2 cells were plated on in a flat bottom 24-weccll plate in DMEM media until >90%
confluence. The cells were stimulated with 10 g/mL LPS and 0.2 mM palmitic acid for 48
hours. The media was replaced with DMEM/F – 12 50/50 media with 100 g/mL of the C-6 labeled exosomes for 30 minutes, 1 hour, 3 hours, 6 hours, and 24 hours. The cells were washed
with DPBS and harvested with trypsin for 5 min. Cells were collected after the addition of 500 l
of DMEM and centrifuged for 10 min at 4oC. Cell pellets were resuspended with PBS containing
5% FBS. Flow cytometric analysis was performed with LSR II (BD Biosciences).
4.2.6

Quantitative rtPCR

RNA was isolated from HepG2 cells in the 24-well plates. The RNA was isolated using
SpinSmart RNA Mini Purification Kit (Denville Scientific Inc, Metuchem, NJ) using the manufacturer’s protocol. The concentration. The cDNA synthesized using a Maxima First Strand
cDNA Synthesis Kit (Thermo Scientific, Rockford, IL) following the manufacturer’s protocol.
The qPCRs were carried out using SYBR Green PCR Master Mix (Life Technologies, Green
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Island, NY) following the manufacturer’s protocol with primers CD98, integrin 1, integrin
v, FAK, Shc, p38 MAPK, TNF , and IL6 using PikoReal Real-Time PCR System (Thermo
Scientific, Rockford, IL). The data was analyzed using threshold cycle (CT) method following
C=(CTtarget-CTHousekeeping)Group1 –(CTtarget-THousekeeping)Group2. The data was derived from 2CT

method. The sequence for human primers: hGAPDH (forward 5'-TTGGTATCGTG-

GAAGGACTCA-3' and reverse 5’- TGTCATCATATTTGGCAGGTTT-3’), hTNF-α (forward
5'-ATCTACCTGGGAGGCGTCTT 3' and reverse 5'-GAGTGGCACAAGGAACTGGT-3'),
hIL6 (forward 5′-GGTACATCCTCGACGGCATCT-3’ and reverse 5′-GT GCCTCTTTGCTGCTTTCAC-3′), hIntegrin 1 (forward 5’-GAAGGGTTGCCCTCCAGA-3’ and reverse
5’-GCTTGAGCTTCTCTGCTGTT-3’), hIntegrin v3

(forward 5’-TTGTTTCAGGAG-

TTCCAAGA-3’ and reverse 5’-TGAAGAGAGGTGCTCCAATA-3’), hFAK (forward 5’-GAAGCATTGGGTCGGGAA-3’ and reverse 5’-CTCAATGCAGTTTGGAGGTGC-3’), hShc (forward 5'-AAGAATTCAACAAGCTGAGTGGAGGCGGC-3’), hp38-MAPK ( forward 5’GCCCAAGCCCTTGCACAT-3’ and reverse 5’-TGGTGGCACAAAGCTGATGAC-3’).
4.2.7

Elisa for secreted cytokines on HepG2 cells treated with Caco2 BBe exosomes

HepG2 cells were grown in a 24-well plate then treated with 100 µg/mL Caco2 BBe exosomes for a period of 24h. The supernatant was collected for the ELISA. Human TNF-α ELISA
kit (ThermoScientific, EH3TNFA, Kalamazoo, MI), Human IL-6 ELISA kit (ThermoScientific,
EH2IL6, Kalamazoo, MI), and Human IFN-γ kit (ThermoScientific, EHIFNG, Kalamazoo, MI)
were used to measure the levels of secreted cytokines using the manufacturer’s protocols.
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4.2.8

Western Blot

HepG2 cells in the 6-well plates were resuspended in RIPA buffer (150 mM NaCl, 1.0%
Triton X-100, 0.5% Sodiumdeoxycholate, 0.1% SDS, 50mM Tris pH. 8.0, Roche phoSTOP and
EDTA-free protease tablets) to extract proteins. The protein concentrations were determined using a DC assay kit (Bio-Rad, Hercules, CA) using the manufacturer’s protocol. Protein samples
were loaded at 15 g onto 12% SDS-PAGE (Bio-Rad, Hercules, CA). The gels were run at 140
V for 1 hour and 15 min at ambient temperature in 1X Trisglycine running buffer. The proteins
were transferred onto 0.22-micron nitrocellulose membrane (Thermo Scientific, Rockford, IL) at
4oC for 1 hour 30 minutes at 100 V. Transfer efficiency to the membrane was checked by ponceau red staining. Membranes were washed with washing buffer (Tris-HCl, NaCl, and Tween-20
(Fisher Scientific, Pittsburgh, PA). The membranes were blocked with 5% nonfat milk prepared
in washing buffer. Primary antibodies were incubated with the membranes overnight or for 1-4
hours at ambient temperature. The antibody loading was GAPDH (1:4000), CD98 (1:500), Integrin 1 (1:500), Integrin 3 (1:500), NFB (1:1000), Shc (1:1000) AKT1/2/3 (1:1000), PI3K
100 (1:1000), PI3K 100 (1:1000), PI3K 100 (1:1000), p38 MAPK (1:1000), P44/42 MAPK
(1:500), SAPK JNK (1:1000), FAK (1:1000), Cav1 (1:500), TGF1 (1:1000), MMP2 (1:1000),
MMP9 (1:1000). HRAS (1:500) in 5% non-fat milk. The membranes were washed with washing
buffer. The membranes were incubated with secondary antibody, anti-rabbit HRP conjugated
(1:4000), for 1 hour at ambient temperature. The membranes were again washed with washing
buffer then incubated with a SuperSignal West Pico Kit (Thermo Scientific, Rockford, IL). The
membranes were exposed to HyBlot ES Autoradiography Film (Denville Scientific, Inc,
Metuchem, NJ) for 15 sec, 30 sec, 1 min, and 5 min, and 10 min. The films were developed using a SERIES 2000A Processor film developer (Kodak, Rochester, NY). Membranes were
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recovered with RestoreTM Western Blot Stripping Buffer (Thermo Scientific, Rockford, IL) protocol prior to additional probing.
Results
4.3.1

Exosome extraction from Caco2 BBe cells

Figure 4.1: Mammalian derived exosome average size (nm) and polydispersity index, charge, and AFM visualization exhibited exosome size.
A) Tabulated size, polydispersity index, and charge B) Size and charge distribution. Number
distribution of particle displayed as histogram. C) AFM. Exosomes were isolated using differential ultracentrifugation. The size and charges were determined using a 90Plus Particle Sizer.
AFM samples were prepared using a stock 100 µg/ml of exosomes for detection.
The extraction of exosomes using differential centrifugation was successful yielding a
small pellet of exosomes from Caco2 BBe cells. The pellets were resuspended in PBS and
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filtered with 0.22 m syringe filters to remove aggregation and non-exosome particles. The
size, charge, distribution charts, and AFM are depicted in Figure 4-1. The population of exosome sizes ranged from 50 – 80 nm as determined by dynamic light scattering (DLS). The
charges were determined to be between -18 to -28 mV (Figure 4-1A). The total protein concentration was determined using a DC assay. The resulting concentrations were all significantly
high allowing further experiments to be conducted. In addition to DLS, the sizes were confirmed using AFM which exhibited exosome populations under 150 nm (Figure 4-1C).
4.3.2

Exosomes exhibit little cytotoxity to HepG2

Figure 4.2: Exosomes derived from Caco2 BBe exhibit no cytotoxicity and high uptake in HepG2 cells.
HepG2 cells were treated with 100 µg/mL of exosomes for 24 hours. A) Cell viability on
cells (percentage over control) after overnight supplementation of 100 µg/ml of exosomes. B) .
Fluorescent Microscopy of HepG2 cell lines supplemented with 100 mg/ml coumarin 6 labelled
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exosomes: control and Caco2 BBe exo (Red: cytosol, Blue: nucleus, and Green: exosomes) C)
HepG2 cells were treated with 100 µg/mL of the c-6 labelled exosomes after stimulation with
LPS and PA for 48 hours. Flow cytometric analysis was performed with LSR II.
The cytotoxicity on the HepG2 cells were tested in vitro with Caco2 BBe exosomes. The
cells little to no toxicity with the exosome treatment and cells remained above 80% viability for
each exosome treatment (Figure 4-2A). We demonstrated that exosomes derived from the tumor
cell lines were totally biocompatible and non-toxic to HepG2 cells at the treatment level for the
experiments.
4.3.3

Fluorescent exosome visualization on HepG2 cells show significant uptake

The uptake of the Caco2 BBe exosomes was examined using fluorescent microscopy and
flow cytometry (Figure 4-2B, C). HepG2 cells significantly took up the Caco2 BBe exosomes
(Figure 4-2B). A time dependent uptake study was performed to gauge the initial effects of inflammation and steatosis on Caco2 BBe exosomes (Figure 4-2C). The initial 30 minutes of uptake showed a slight increase in uptake when compared the control This was also observed in the
1-hour uptake time point. There was a saturated signal for the exosome uptake at 3- and 6-hours
for the exosome treatment used. The slight shift in uptake when the HepG2 cells were stimulated
with PA. LPS stimulation remained consistent for both experiments. Between both trials, either
the PA or LPS treatment exhibited shifts in uptake. The initial increase in uptake may attribute to
the progression of liver diseases with inflammation and steatosis. HepG2 cells with pre-existing
inflammation and steatosis that exhibited an initial increase in uptake. This may support that livers suffering from such diseases as NAFLD and NASH could potentially be more vulnerable to
CRC metastasis[175]. Further study of a time dependent uptake of Caco2 BBe exosomes with
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HepG2 cells with varying degrees of inflammation and steatosis would be necessary in order to
correlate the relationship between the uptake and the disease state.
4.3.4 HepG2 cells exhibited increased expression of Iβ1, Iβ3, and FAK and downstream proteins in the integrin pathway following treatment with exosomes derived from Caco2
BBe

Figure 4.3: HepG2 cells exhibited increased expression of I1, I3, and FAK and
downstream proteins in the integrin pathway following treatment with exosomes derived from Caco2 BBe
HepG2 cells were treated with 100 µg/mL of exosomes for 24 hours. A) Fold change of mRNA
levels were normalized to the untreated cells following subsequent RNA extraction and PCR.
Plotted are means + SEM. * represents P<0.5, ** represents P<0.05. B) Primary antibody incubation was carried out at 1:500 (CD98, integrin 1, integrin 3, FAK) and 1:4000 GAPDH overnight. C) Primary antibody incubation was carried out at 1:1000 (PI3K 100, PI3K 100, PI3K
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100) and 1:4000 GAPDH overnight. D) Primary antibody incubation was carried out at 1:1000
p38 MAPK, P44/42 MAPK, SAPK JNK) and 1:4000 GAPDH overnight. Secondary antibody
incubation was carried out at 1:4000 for 1 hour at ambient temperature. Blocking was carried out
with 5% nonfat milk.
To investigate the potential changes in CD98, Integrin 1, and Integrin 3 after Caco2
BBe exosome treatment qPCR and Western blot. HepG2 cells were treated with exosomes from
Caco2 BBe to investigate the biological response to the exosome communication (Figure 4-3).
Western blot and qPCR analysis exhibited no significant change in protein and mRNA levels for
CD98. The mRNA levels for integrin 1, integrin 3, and FAK were significantly increased
while CD98 mRNA levels should no significant change (Figure 4-3A). Integrin 1 expression
was also noticeably increased with exosome treatment in HepG2 cells which was calculated to be
a 1.54-fold increase. Integrin 3 showed the most increase from the control in HepG2 which was
calculated to be a 4.78-fold increase. FAK protein expression was calculated to be a 5.19-fold
increase.
Western blot data was obtained on key proteins involved in the CD98-Integrin signaling
pathway. Caco2 BBe exosome treatment increased PI3K 100, PI3K 100, p38 MAPK, and
SAPK JNK. The overall fold change was calculated via densitometry normalized to the control.
From data obtained, PI3K 100, p38 MAPK, and SAPK JNK presented the largest upregulation
after Caco2 BBe exosome treatment supporting that the exosome may be playing a role in inducing the PI3K and MAPK pathways associated to integrin activation. Whether or not this is a direct caused from integrin upregulation to downstream upregulation or stimulated upregulation
cause by a global upregulation of expression by the exosome remains to be elucidated.
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4.3.5 Exosomes derived from Caco2 BBe increased the mRNA levels and secretion of IL6
and the expression of NFκB, TGFβ1, and MMP9 in HepG2 cells

Figure 4.4: Exosomes derived from Caco2 BBe increased the mRNA levels and secretion of IL-6 and the expression of NFκB, TGFβ1, and MMP9 in HepG2 cells.
HepG2 cells were treated with 100 µg/mL of exosomes for 24 hours. A) Fold change of mRNA
levels were normalized to the untreated cells following subsequent RNA extraction and PCR B)
Secretion of IL6 and TNF a was detected from the collected media after exosome treatment using prepared ELISA plates. Secretion levels were normalized to the untreated samples. Plotted
are means + SEM. * represents P<0.5, ** represents P<0.05. C) Primary antibody incubation
was carried out at 1:1000 (NFkB, TGFb1, MMP9) and 1:4000 GAPDH overnight at 4oC followed by secondary antibody at 1:4000 for 1 hour at ambient temperature. Blocking was carried
out with 5% nonfat milk.
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Proinflammatory effects of the Caco2 BBe exosomes were examined using qPCR,
ELISA, and Western Blot (Figure 4-4). The mRNA levels of IL6 were observed to be significantly upregulated after treatment while there was no noticeable increase in TNF- mRNA levels (Figure 4-4A). ELISA demonstrated that Caco2 BBe exosome treatment increased IL6 secretion over 2-fold over the untreated while there was a 0.16-fold increase in TNF- secretion (Figure 4-4B). Caco2 BBe exosomes increased TNF-α secretion by 0.16-fold.
Western blot data was obtained on proteins involved in proinflammatory pathways (Figure 4-4C). NFB, TGF1, and MMP9 were increased the exosome treatment. NFB
exhibited a 2.57-fold increase, TGF1 exhibited a 1.38-fold increase, and MMP9 exhibited a
2.32-fold increase in expression as calculated by densitometry.
4.3.6 Exosomes derived from Caco2 BBe increased the organization of CD98/I1 complexes
(Integrin clustering)

Figure 4.5: Exosomes derived from Caco2 BBe increased the organization of
CD98/I1 complexes (Integrin clustering).
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Cells were then supplemented with 50 µg/mL Caco2 BBe exosomes for 12 hours. Cells
were stained for CD98 (Red), I1 (Green), and nucleus (Blue) for surface expression. A) Untreated HepG2 cells B) HepG2 cells treated with Caco2 Bbe exosomes.
Although the CD98 expression was not altered, microscopy was performed to investigate
the interaction of CD98 to integrin. The data suggests that upon Caco2 BBe exosome treatment,
CD98 will form more clustered complexes with integrin more readily which may help explain
mechanisms for the development of the pre-metastatic tumor environment. It has been reported
that integrin clustering is associated to CD98 activation [101]. The CD98 activation thus could
be determined by this overall change in Integrin 1 distribution on the cell surface and could provide more insight in how the CD98-integrin pathway is being altered with CRC exosome treatment.
4.3.7 Proteomic data showed potential proteins involved in integrin, PI3K, MAPK, and
MMP pathways
The proteomic and lipid analysis of the Caco2 BBe exosomes presented a large array of
proteins of various functions and distinct lipid profile (Appendix Figure #). From the proteomics, 446 unique proteins were identified. Of the 446, 29 were linked to tumor related functions. The proteins were then categorized by potential entry points into the CD98-Integrin signaling pathway (Figure 4-6). Proteins that were identified could alter or promote integrin signaling,
PI3K-Akt signaling, MAPK signaling, and MMP2/MMP9 signaling directly to promote angiogenesis, invasiveness, and proliferation [176-204].
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Figure 4.6: Proteins in the Caco2 BBe exosomes that are involved in the CD98-Integrin signaling pathway.
Proteomic data was obtained from Bioproximity. Proteins identified were categorized according
to function to determine potential entry points to the pathway.
Discussion and Conclusion
The data obtained was primarily to interrogate the biological effects of treatment of
HepG2 cells with the colorectal cancer cell line Caco2 BBe exosomes. The data demonstrated
that the exosomes were similar in size to the exosomes in literature [205]. In addition, the HepG2
cell lines could readily take up the Caco2BBe exosomes. This demonstrated the idea that exosomes form CRC to HCC form intercommunication between cells and can be readily exchanged
between one another. The exosome treatment used in the experiment was not cytotoxic to the
HepG2 cells. An interesting observation is that HepG2 cells with inflammation or steatosis prior
to Caco2 BBe exosome treatment exhibited a slight increase in initial exosome uptake. Thus, it
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may be possible that livers suffering from NAFLD or NASH could be subject to greater exosome
uptake. In terms of metastasis from CRC on the liver, promotion of exosome uptake on a diseased liver could promote the metastatic environment which has been demonstrated in the literature [173]. One such report demonstrated that patients suffering from NAFLD and NASH exhibited an increased detection of colorectal neoplasia [206]. This observation could also be useful to
associate steatosis in liver cells in diseases such as NAFLD could take tumor secreted exosomes
to increase the risk of metastasis.
Our data demonstrated that integrins 1 and 3 were highly upregulated in HepG2 cells
treated with Caco2 BBe exosomes. In literature, CRC-derived exosomes have only been shown
to affect the MAPK pathway through ERK and the CXCR4 axis [173, 174]. This data then provides a novel role in the exosome communication between HepG2 and Caco2 BBe cells. In literature integrin 3 and  are implicated in liver metastasis from CRC [207-211]. While it was
shown that upon CRC metastasis in the liver there is an upregulation in CD98, Integrin 1, Integrin , and FAK [79] we present that the exosomes derived from Caco2 BBe could induce a similar upregulation for integrin 1, integrin , and FAK. When considering another report that explains that metastasis by Caco2 BBe on mouse livers pretreated with CRC derived exosomes
[173] we can associate that the CRC derived exosomes can induce a metastatic phenotype. In the
case of our experiment, the hepatocellular carcinoma cell line (HepG2) could be said to exhibit a
greater tumorigenic phenotype.
CD98 is a multifunctional protein that has been implicated in activating integrin 1 and
3 [65, 66], and CD98 activates integrin by increasing integrin affinity to other ligands [67]. Interestingly, knockout of CD98 demonstrated that CD98 was not required for integrin expression,
affinity, and adhesion; however, disruption caused defects in cell spreading and cell migration
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which demonstrated that CD98 is necessary for efficient integrin 1 signaling [72, 73]. One of
the interesting findings is that CD98 and I1 interaction was ‘clustered’ in the microscope images. The integrin signal became more orderly in its association with CD98 which could contribute to the activation of CD98 to induce the integrin signaling. In literature, the integrin ‘clustering’ has been reported to be a sign of CD98 activation [101]. So, although our CD98 expression
was not increased, perhaps, the CD98 induced integrin signaling is upregulated as a result of
Caco2 BBe exosome treatment.
Integrins play a major role in cell adhesion and in cell signaling of downstream targets
such as FAK, PI3K, MAPK, and NFB. Quantitative PCR exhibited increased I1, I3, FAK,
and inflammatory cytokine mRNA levels in HepG2 which indicate that the communication between Caco2 BBe exosomes are increasing the proteins involved in integrin signaling. The Elisa
data exhibited an increase in IL6 and TNF  secretion with supported the qPCR results. Western
blot demonstrated increased FAK, PI3K 100, PI3K 100, p38 MAPK, SAPK JNK, NFB,
TGF1, and MMP9. Interestingly, promotion of MMP2 and MMP9 could be related to the increase in CD98 activation and binding to integrin 1 [76, 212]. The ability for the Caco2 BBe
exosomes to promote inflammation was also noted. The role of IL-6, TNF-α, and NFκB in hepatocellular HCC is complex and starts with chronic liver inflammation that transitions to cirrhosis,
and eventually into HCC [213]. The proinflammatory properties could then be extended as a
function to promote the progression of liver disease. The upregulation of TGF 1 is another interesting result. TGF 1 is linked to hepatic fibrosis [214]. The increased CD98 activity and integrin 1 expression could be linked to profibrotic function of TGF 1 [94, 95]. Mitogen-activated protein kinase (MAPK) p38 is involved in the apoptotic process and has been shown to respond to external stress to induce the expression of proinflammatory cytokines [215].
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Phosphoinositide 3-kinase (PI3K) is expressed as a heterodimer containing a p110 catalytic subunit, p110 which is involved in angiogenesis and p110 which is involved in inflammation, and
regulatory subunit [216, 217].
The proteomic data obtained was used to bridge possible linked to the signaling pathways. While we do observe the upregulation integrin, it is also important to know that the Caco2
BBe exosomes contain a variety of different proteins which could affect the pathway at different
points which are directly and indirectly linked to integrin. From our data, we present that the
Caco2 BBE exosomes can effectively increase integrin expression which has been documented
to promote tumor growth and development. Our paper then bridged a possible gap between what
is known by demonstrating that hepatocyte metastatic environments can be induced through the
treatment of CRC-derived exosomes prior to metastasis by CRC cells. Taken together, the communication between Caco2 BBe cells via exosomes to HepG2 can induce integrin signaling.
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5

TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE USING PLANT
DERIVED EXOSOMES
Exosomes are nanovesicles that are secreted by cells and participate in intercellular com-

munication via exchange of cargo such as oligonucleotides, lipids, and proteins. Recently, there
has been investigations of the intercommunication between plant derived exosomes (PDEs) and
mammalian cells. Our aim is to demonstrate the therapeutic potential PDEs for treating inflammation and steatosis associated to nonalcoholic fatty liver disease (NAFLD). PDEs derived from
grapefruit, garlic, and carrots were extracted after homogenization of the plants and isolated by
differential centrifugation. Characterization of PDEs was carried out by dynamic light scattering
and atomic force microscopy. HepG2 was supplemented with PDEs followed by LPS and palmitic
acid. Mice were given a high fat diet for 9-10 weeks to NAFLD and were orally given garlic
derived exosomes post and concurrently for the duration of the diet. Fluorescent microscopy and
flow cytometry were used to determine uptake. H&E staining was performed on liver tissue to
examine liver steatosis. Western blot and qPCR experiments were conducted to probe the expression of inflammatory markers and proteins in the CD98-integrin pathway. Nanosized PDEs were
successfully isolated and the measured sizes were observed around 80-200 nm. HepG2 cells
demonstrated significant uptake of each PDEs and treatment after LPS exhibited significant antiinflammatory effects and palmitic acid treated HepG2 cells demonstrated reduced CD98-integrin
signaling protein expression which were predominantly demonstrated with the treatment of garlic
PDEs. Similar reductions in pro-inflammatory mediators and the CD98-intregrin signaling protein
expression. Noticeable reductions in levels of steatosis in mice given GDEs. Together, our data
implicates using garlic PDEs could be a promising new therapeutic tool to treat liver inflammation
and steatosis associated with NAFLD.
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Background
Nonalcoholic fatty liver disease, NAFLD, is a very common liver disease in adults and
children in the western society due to the high fat western diets and is defined as lipid accumulation, steatosis, in the liver by nonalcoholic means. [1, 2]. Typically, NAFLD is asymptomatic but
prolonged disease state has been correlated to the development of more serious liver diseases
such as NASH, liver fibrosis, cirrhosis, and even hepatocellular carcinoma as a result of prolonged damage from inflammation and oxidative stress in NAFLD [218]. Thus, interest in
NAFLD has recently gained momentum. Treatments that are being investigated are insulin sensitizers, antioxidants, hepatocyte-protective agents, anti-dyslipidemias, RAS blockers, incretin-related agents, and anti-obesity drugs [4]. However, currently there is not an approved drug on the
market that treats NAFLD and lifestyle changes such as exercise and diet remain the most effective at reducing the risk of the disease progressing [2].
CD98 is a multifunctional protein that has been implicated in activating integrins 1 and
αvβ3 [65, 66] and has been heavily studied in inflammation-related diseases in the intestinal tract
[120, 123]. CD98 has been studied to be a key player in tumorigenesis due to its role in the
CD98hc activating integrin signaling to promote tumor progression via angiogenesis, invasiveness, and proliferation in addition promoting malignant transformation of cells (metastasis) [81,
98]. Interestingly, knockout of CD98 demonstrated that CD98 was not required for integrin expression, affinity, and adhesion; however, disruption caused defects in cell spreading and cell migration which suggests that CD98 is necessary for efficient integrin 1 signaling [72, 73]. In addition, targeting CD98 has shown promise as a target for decreasing inflammation associated to
colitis [123]. More importantly, reducing CD98 was reported to decrease inflammation in HepG2
cells and attenuate hepatic steatosis in high fat diet mice [18].
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Exosomes are nano-sized vesicular bodies that are excreted from a variety of cells. Exosomes come in a wide array of sizes from 20 – 200 nm and carry cargo consisting of nucleic acids such as mRNA, miRNA, siRNA and also carry a varied array of proteins such as membrane
transport and fusion proteins, tetraspannins, heatshock proteins, proteins associated to metabolism and coagulation, adhesion proteins, ect [47]. What was first reported to be a ‘garbage disposal’ vehicle [48, 49] was later determined to play a role in intercellular communication [50],
cancer development [51], antimicrobial defense [52], immune response [53], and various other
biological functions. Exosomes have also been studied as a tool for their diagnostic and therapeutic potentials for disease as well [47]. However, research was primarily performed on mammalian derived exosomes and their interaction with various mammalian cells until the discovery
of exosome-like vesicular bodies in plants in 2006 [55]. This discovery of plant derived exosomes, PDEs, led to further investigation into interspecies cellular communication. Ju et al reported that the grapes contained PDEs and administration could stimulate stem cell proliferation
and could protect mice from dextran sulfate sodium (DSS) induced colitis [60]. Wang et al isolated PDEs from grapefruit and reported that intestinal macrophages selectively uptook the PDEs
and presented significant inhibition of IL-6 and IL-1 during DSS induced colitis [61]. Mu et al.
isolated from grapes, grapefruit, ginger, and carrots and demonstrated that PDEs anti-inflammatory responses with gut host cells through the stimulation of IL-10 and inhibition of HO-1 [62].
Lemon derived exosomes were isolated from lemon juice and has shown to stimulate TRAILinduced apoptosis in vitro and suppress the growth of a CML xenograft model [63].
From what has been published, there is a surprising lack of information regarding CD98
in its role towards liver disease other than our previously published work. The objective of the
study is to determine what effect PDEs have on inflammation and on the CD98-induced integrin
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1 signaling pathway. Grapefruit, garlic, and carrots are known to be beneficial for maintaining a
healthy liver. These plants are rich in vitamin C, vitamin A, flavonoids, and antioxidants. In addition, these plants have shown anti-inflammatory properties [219-221]. In this study, we interrogated the possible interaction of PDEs from grapefruit, garlic, and carrots on mammalian cells and
their specificity to liver epithelial cells. Nano-sized PDEs were extracted from each plant and
treated on macrophages, colon cells, and liver cells. The study showed that the PDEs were, as expected, taken up by the macrophages cell line which was used as positive endocytosis cells. PDEs
were not specifically taken up by intestinal epithelial cells. Interestingly, PDEs were specifically
endocytosed by the liver epithelial cells. The large uptake of PDEs by liver epithelial cells
(HepG2) lead to a dramatic decrease of the inflammation/oxidation on HepG2 after exposure to
LPS. We then investigated the potential therapeutic properties for targeting the induced integrin
1 signaling pathway using an in vitro and in vivo nonalcoholic liver disease model. PDE treatment led to decreased CD98, FAK, Shc, Fyn, NFB, and MAPK expression after palmitic acid
supplementation and high fat diet in addition to showing large anti-inflammatory and anti-steatosis properties. The data presented in this paper showed that treatment of PDEs from grapefruit,
garlic, and carrot can potentially treat upregulated integrin 1 signaling in hepatic diseases
through the reduction of CD98 and downstream targets of the pathway.
Methods
5.2.1

Extraction of Exosomes from Plants

Grapefruits, carrots, and garlic were homogenized in sterile PBS using a mechanical homogenization (Blender, Oster, USA). The plants were peeled prior to homogenization to avoid
contamination by the skin of the plants. The homogenized samples were centrifuged at 2000 x g
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for 10 min at 4oC to remove the pulp. The supernatant was centrifuged at 10,000 x g for 30 min
at 4oC to remove cell debris. The supernatant was vacuum filtered to remove low density solids.
The samples were ultracentrifuged at 100,000 x g for 1-2 hours at 4oC. The pellets were washed
with sterile PBS and ultracentrifuged at 100,000 x g for 1 hour at 4oC. The pellet was resuspended in sterile PBS. The samples were then analyzed using a 90 Plus Particle Size Analyzer
(Brookhaven Instruments Corporation, Holtsville, USA) to determine the size and the charges.
5.2.2

Visualization of plant derived exosomes

PDEs from grapefruit, garlic, and carrot were labeled using 1 mM coumarin-6 (SigmaAldrich, St Louis, MO). Coumarin-6 based dyes are uptaken into membranes and are fixed on
the bilayer [14]. Exosome (50 g) in were incubated with 1 m C-6 for 30 min at ambient temperature. The C-6-labelled exosomes were purified using an Exosome Spin Column (Life Technologies, Green Island, NY) using the manufacturer’s protocol. Raw 264.7, Coco2 BBe, and
HepG2 cells were grown on Lab-Tek II CC2 Chamber Slides (Thermo Fisher Scientific Inc.,
Waltham, MA) until >90% confluence in Dulbecco’s Modification of Eagle’s Medium, DMEM,
with 1 g/L glucose L-glutamine & sodium pyruvate (Mediatech, Inc., Manassas, VA). The media
was changed to Dulbecco’s Modification of Eagle’s Medium / Ham’s F-12 50/50 Mix, DMEM/F
– 12 50/50 with L-glutamine & 15 mM HEPES (Mediatech, Inc., Manassas, VA) and then supplemented with the C-6 labelled PDEs for 24 hours. Inflammation was stimulated with Lipopolysaccharides, LPS, (Sigma-Aldrich, St Louis, MO) for 4 hours at 37oC. After incubation the media was drained, and the cells were washed with Dulbecco’s Phosphate Buffered Saline, DPBS,
with magnesium and calcium (Mediatech, Inc., Manassas, VA). Cells were fixed 4% formaldehyde (Electron Microscope Sciences, Hatfield, PA) for 15 min. The cells were then incubated
with 1:60 AlexaFluro 568 phalloidin (Life Technologies, Carlsbad, USA) in DPBS 45 min and
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fixed with Vecta Shield with DAPI (Vector Laboratories Inc, Burlingame, USA). Slides were
imaged on a Fluorescent microscope (Olympus, Shinjuku, Tokyo).
5.2.3

Atomic Force Microscopy

Atomic force microscopy (AFM) samples were prepared by placing a drop of 100 g/mL
PDEs onto mica slides for 30 min. The mica slides were washed with PBS and dried for 24
hours. The AFM samples were analyzed on a SPA 400 (Seiko instruments, Chiba, Japan) using
soft tapping mode.
5.2.4

Transmission Electron Microscopy

The PDEs pellets were resuspended in ddH2O to remove PBS salts. The PDEs were
fixed with glutaraldehyde containing 2.5% cacodylate buffer (0.1 mol/L, pH7) at 4oC. The samples were rehydrated with increasing alcohol concentrations of 30%, 50%, 70%, 90%, and 100%
vol/vol for 2 min each. The samples were incubated with hexamethyldisilazine for 5 min and
dried under a ranged hood. The plots were fixed on an aluminum support with carbon-adhesive
glue and coated with gold phaladium (Spotter Coater SC7640). The samples images were taken
under transmission electron microscope (Cambridge Instruments Stereoscan S).
5.2.5

Cell Cytotoxicity Test

Raw 264.7, Coco2 BBe, and HepG2 cells were plated on in a flat bottom 96 well plate in
DMEM media until >90% confluence. The media was replaced with DMEM/F – 12 50/50 media
with 100 g/mL – 1 mg/mL of the PDEs overnight. Then 10 L MTT reagent (Trevigen, Gathnerburg, MD) for 2 hours followed by the addition of 100 L of the detergent (Trevigen, Gathnerburg, MD) for 4 hours. The plate was read at 550 nm on a Synergy H1 Microplate reader (BioTek, Winooski, VI).
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5.2.6

Free Fatty Acid Preparation

A 100 mM solution of palmitic acid stock was dissolved in 100 mM NaOH at 70oC. A
10% BSA solution was prepared in ddH2O at 55oC. The palmitic acid conjugated to BSA by preparing 10 mM solution of PA with 1% BSA at 55oC for 30 minutes. The solution was cooled and
filtered with a 0.22-micron filter. The pH of the stock PA solution is 7.2.
5.2.7 Cell Culture
LPS treatments: Raw 264.7, Caco2 BBe, and HepG2 cells were grown in flat bottom 6
well and 24 well plates. The cells were grown to >60% confluence in DMEM and the media was
replaced with DMEM/F – 12 50/50 media with exosome depleted FBS to grow to >90% confluence. After confluence, 50 g/mL of the PDEs were supplemented to each cell for 24 hours. Inflammation was induced with the addition of lipopolysaccharides (LPS) for 4 hours at 37oC.
FFA treatment: HepG2 cells were grown in flat bottom 6 well and 24 well plates. The
cells were grown to >80% confluence in DMEM and the media was supplemented with 0.1 mM
for 24 hours and 0.2 mM for 48 hours. Inflammation was induced with the addition of lipopolysaccharides (LPS) in addition to the fatty acid treatment. The media was replaced with DMEM/F
– 12 50/50 media with exosome depleted FBS post-treatment with PA and was supplemented
with 50 g/mL of exosomes derived from grapefruit, garlic, and carrot for 24 hours.
5.2.8

Total Lipid Extraction and Analysis from Plant Derived Exosomes (Lipidomics)

Lipids from grapefruit, garlic, and carrot were analyzed by Kansas Lipidomics Research
Center (Manhattan, USA). The lipid extractions were analyzed on a tandem mass spectrometry
with a collision cell on Applied Biosystem API 4000 (AB Sciex, Framingham, USA). Lipids
were extracted by adding 80 l of PDEs to 100 l of chloroform and methanol with agitation.
Then 100 l of chloroform and distilled H2O was added to the solution with agitation followed
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by centrifugation at 100 x g for 5 min. The bottom layer was collected and 100 l was added to
the original tube for centrifugation at 100 x g for min. The bottom layer was collected and added
to the bottom layer collect. The process was repeated once more. The combined bottom layer
was then added to 100 l of KCl with agitation. The bottom layer was collected and dried overnight.
5.2.9

Total Protein Analysis from Plant Derived Exosomes (Proteomics)

Plant derived exosomes were pelleted down 100 g/mL for 2 hour at 130,000 x g in a
TLA 100.3 (Beckman Coulter, Atlanta, USA). The supernatant was removed and the pellets
were stored in dry ice to be sent to Bioproximity. The pellets were analyzed by tandem mass
spectrometry on a Q-Exactive Orbitrap (Bioproximity, Chantilly, USA) for exosome proteome.
5.2.10 qPCR of HepG2, Caco2 BBe, and Raw 264.7
RNA was isolated from HepG2, Caco2 BBE, and Raw 264.7 cells in the 24 well plates.
The RNA was isolated using SpinSmart RNA Mini Purification Kit (Denville Scientific Inc,
Metuchem, NJ) using the manufacturer’s protocol. The concentration. The cDNA synthesized
using a Maxima First Strand cDNA Synthesis Kit (Thermo Scientific, Rockford, IL) following
the manufacturer’s protocol. The qPCRs were carried out using SYBR Green PCR Master Mix
(Life Technologies, Green Island, NY) following the manufacturer’s protocol with primers
CD98, integrin v4, Cav-1, FAS, and IL1B using PikoReal Real-Time PCR System (Thermo
Scientific, Rockford, IL). The data was analyzed using threshold cycle (CT) method following
C=(CTtarget-CTHousekeeping)Group1 –(CTtarget-THousekeeping)Group2. The data was derived from 2CT

method. Sequences for human and mice primers listed on Appendix Table 2.
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5.2.11 Western Blot of HepG2, Caco2 BBe and Raw 264.7
HepG2 cells in the 6 well plates were resuspended in RIPA buffer (150 mM NaCl, 1.0%
Triton X-100, 0.5% Sodiumdeoxycholate, 0.1% SDS, 50mM Tris pH. 8.0, Roche phoSTOP and
EDTA-free protease tablets) to extract proteins. The protein concentrations were determined using a DC assay kit (Bio-Rad, Hercules, CA) using the manufacturer’s protocol. Protein samples
were loaded at 15 g onto 12% SDS-PAGE (Bio-Rad, Hercules, CA). The gels were run at 140
V for 1 hour and 15 min at ambient temperature in 1X Trisglycine running buffer. The proteins
were transferred onto 0.22 micron nitrocellulose membrane (Thermo Scientific, Rockford, IL) at
4oC for 1 hour 30 minutes at 100 V. Transfer efficiency to the membrane was checked by ponceau red staining. Membranes were washed with washing buffer (Tris-HCl, NaCl, and Tween-20
(Fisher Scientific, Pittsburgh, PA). The membranes were blocked with 5% nonfat milk prepared
in washing buffer. Primary antibodies were incubated with the membranes overnight or for 1-4
hours at ambient temperature. The antibody loading was GAPDH (1:4000), CD98 (1:1000),
AKT1/2/3 (1:1000), FAK (1:1000) in 5% non-fat milk. The membranes were washed with washing buffer. The membranes were incubated with secondary antibody, anti-rabbit HRP conjugated
(1:4000) and anti-mouse HRP conjugated (1:4000), for 1 hour at ambient temperature. The
membranes were again washed with washing buffer then incubated with a SuperSignal West
Pico Kit (Thermo Scientific, Rockford, IL). The membranes were exposed to HyBlot ES Autoradiography Film (Denville Scientific, Inc, Metuchem, NJ) for 15 sec, 30 sec, 1 min, and 5 min,
and 10 min. The films were developed using a SERIES 2000A Processor film developer (Kodak,
Rochester, NY). Membranes were recovered with RestoreTM Western Blot Stripping Buffer
(Thermo Scientific, Rockford, IL) protocol prior to additional probing
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5.2.12 Visualization of PDE uptake and CD98 expression after transfection of CD98
siRNA and palmitic acid supplementation of HepG2 cells
HepG2 cells were grown on Lab-Tek II CC2 Chamber Slides until >60% confluence.
CD98 siRNA (Santa Cruz, Dallas, TX) was complexed with oligofectamine™ reagent (Life
Technologies, Green Island, NY) following manufacturer’s protocol. The siRNA was transfected
into HepG2 cells for 4 hours at 37oC in DMEM without serum or antibiotics. DMEM media containing FBS was added to the cells and was let to grow to 90% confluency. The media was supplemented with 0.1 mM palmitic acid for 24 hours and 0.2 mM palmitic acid for 48 hours followed by supplementation of C-6 labeled PDEs for 24 hours. The media was drained and the
cells were washed with DPBS with magnesium and calcium. Cells were fixed 4% formaldehyde
(Electron Microscope Sciences, Hatfield, PA) for 15 min. The cells were blocked with blocking
buffer (1X PBS/5% BSA/0.3% Triton™ X-100) for 1 hour. The cells were then incubated with
1:1000 anti-CD98 (Santa Cruz, Dallas, TX) in antibody dilution media (1X PBS/1% BSA/0.3%
Triton™ X-100) overnight at 4oC. The slides were rinsed 3 times with PBS. Anti-goat IgG (H +
L) CF488A (Sigma-Aldrich, St Louis, MO) was placed on the slides for 1 hour without light.
Slides were treated with DAPI for 10 min at ambient temperature. The slides were then covered
in Prolong® Gold Antifade Reagent (Cell Signaling Technology, Danvers, MA). Slides were imaged on a Fluorescent microscope (Olympus, Shinjuku, Tokyo).
5.2.13 Western blot and qPCR analysis of HepG2 cells treated with PDEs after PA and LPS
supplementation
HepG2 cells were plated on in a flat bottom 6 well and 24 well plate in DMEM media until >90% confluence. Western blot analysis was taken from the HepG2 cells treated with 0.2 mM
PA over a period 48 hours. Primary antibody incubation was carried out at 1:500 (CD98, integrin
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b1, R-RAS, H-RAS, Fyn, CD36), 1:1000 (NF Kappa b, FAK, AKT, Shc, p38 MAPK, p85/p55
PI3K, P100a PI3K, P100b PI3K), 1:2000 p44/p42 MAPK, and 1:4000 GAPDH overnight at 4oC
followed by secondary antibody at 1:4000 for 1 hour at ambient temperature. The membranes
were incubated with a SuperSignal West Pico Kit (Thermo Scientific, Rockford, IL). The membranes were exposed to HyBlot ES Autoradiography Film (Denville Scientific, Inc, Metuchem,
NJ) for 15 sec, 30 sec, 1 min, and 5 min, and 10 min. The films were developed using a SERIES
2000A Processor film developer (Kodak, Rochester, NY). Membranes were recovered with RestoreTM Western Blot Stripping Buffer (Thermo Scientific, Rockford, IL) protocol prior to additional probing. Quantitative PCR was measured using 0.1 mM of PA over a period of 48 hours.
RNA was isolated HepG2 cells in the 24 well plates. The RNA was isolated using SpinSmart
RNA Mini Purification Kit (Denville Scientific Inc, Metuchem, NJ ) using the manufacturer’s
protocol. The RNA was quantified using a Synergy H1 Microplate reader. Stock RNA was prepared at equal concentration. The cDNA synthesized using a Maxima First Strand cDNA Synthesis Kit (Thermo Scientific, Rockford, IL) following the manufacturer’s protocol. The qPCRs
were carried out using SYBR Green PCR Master Mix (Life Technologies, Green Island, NY)
following the manufacturer’s protocol with primers CD98, integrin 1, FAK, p38 MAPK, Shc,
and MMP2 using PikoReal Real-Time PCR System (Thermo Scientific, Rockford, IL). The data
was analyzed using threshold cycle (CT) method following C=(CTtarget-CTHousekeeping)Group1
–(CTtarget-THousekeeping)Group2. The data was derived from 2-CT method. The sequence for human primers listed on Appendix Table 2.
5.2.14 Weights of mice fed HFD and garlic PDE gavage
Mice were fed a high fat diet C57b6 mice were fed a 60% fat diet (Research Diets, Inc,
D12492, New Brunswick, NJ) and a 10% fat control diet (Research Diets, Inc, D12450B, New
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Brunswick, NJ) for a period of 9 weeks and 10 weeks. Post-treatment of mice was carried out
with 0.5 mg/mL of garlic derived exosomes and 1x PBS by oral gavage daily for 3 weeks after
initial 10-week high fat diet and low-fat diet. Weights were recorded 3 times a week to measure
weight loss and mice were sacrificed after the 3-week period. Concurrent treatment with garlic
derived exosomes was carried out during the duration of the 9-week high fat diet. Mice were
treated with 0.5 mg/mL of garlic derived exosomes and 1x PBS by oral gavage daily and 1x PBS
for 9-weeks. Mice were weighed daily and mice groups (n=6) were sacrificed at 3 weeks, 6
weeks, and 9 weeks.
5.2.15 Flowcytometry
Isolation of liver cells was performed. Briefly, liver was perfused with HBSS with 5% FBS
and 2 mmol/L EDTA at 37°C to remove blood. A large piece of liver was excised and cut longitudinally, washed of blood contents, cut into pieces 0.5 cm in length, and subjected to two sequential 20-minute incubations in HBSS with 5% FBS and 2 mmol/l EDTA at 37°C with agitation.
After each incubation step, media containing debris was discarded. The remaining tissue was
minced and incubated for 11 minutes in HBSS with 5% FBS, 1.5 mg/mL collagenase VIII (SigmaAldrich), and 40 U/mL DNase I (Roche Diagnostics, Indianapolis, IN) at 37°C in agitation. Cell
suspensions were collected and passed through a 100-μm strainer and pelleted by centrifugation at
300 g. To perform flow cytometry analysis, the Abs below were used. Total liver cells were resuspended in phosphate-buffered saline (PBS) containing 5% fetal bovine serum (FBS). Live and
dead cells were determined by using the fixable Aqua Live/Dead cell staining kit (Invitrogen
Thermo Fisher Scientific, Waltham, MA) according to the manufacturer’s protocol. Cells were
stained at 4oC for 30 minutes with fluorescence-labeled Abs. After incubation, samples then were
washed 3 times in PBS containing 5% FBS and then cell were fixed/ permeabilized by
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fixation/permeabilization kit (eBioscience). Afterward, cells were incubated at 4oC with anti-Albumin and anti- HNF4α for 30 minutes followed by stain with PE- and PerCP-Cy5.5-linked secondary antibody, respectively. Flow cytometric analysis was performed with LSR II (BD Biosciences).
5.2.16 Gene expression of inflammatory and NAFLD markers on liver and colon tissue
RNA was isolated liver tissue after sonication in lysis buffer. The RNA was isolated using
SpinSmart RNA Mini Purification Kit (Denville Scientific Inc, Metuchem, NJ ) using the manufacturer’s protocol. The RNA was quantified using a Synergy H1 Microplate reader. Stock RNA
was prepared at equal concentration. The cDNA synthesized using a Maxima First Strand cDNA
Synthesis Kit (Thermo Scientific, Rockford, IL) following the manufacturer’s protocol. The
qPCRs were carried out using SYBR Green PCR Master Mix (Life Technologies, Green Island,
NY) following the manufacturer’s protocol with primers CD98, CD36, MMP9, MMP2, TGF ,
TNF , INF , FAS, IL6, IL1, IL8, PPAR , PPAR  PPAR , IL10, SREBP, CD106, APOA,
ACAT, ABCA, and SCD using PikoReal Real-Time PCR System (Thermo Scientific, Rockford,
IL). The data was analyzed using threshold cycle (CT) method following C=(CTtarget-CTHousekeeping)Group1

–(CTtarget-THousekeeping)Group2. The data was derived from 2-CT method. Se-

quences for mouse primers listed on Appendix Table 2.
5.2.17 Hematoxylin and Eosin Y staining of liver tissue from mice fed HFD and garlic
gavage
Tissues were embedded in paraffin. Dewaxing of the slides was performed using two 10minute washes with xylene, two washes with 95% ethanol for one minute, and two washes with
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75% ethanol for one minute. The slides were stained with Mayer’s Hematoxylin (HMM500,
Scytek, Logan, Utah) for 5 minutes followed by washing with diH2O. Slides were stained with
Eosin Y Solution (EYB500, Scytek, Logan, Utah) for 2-3 minutes. Slides were rinsed 100% ethanol and air dried before mounting with Cytoseal XYL (8312-4, ThermoScientific, Kalamazoo, MI,
49008).
Results
5.3.1

Isolation and characterization of PDEs

The extraction of PDEs using differential centrifugation was successful yielding a large
pellet of exosomes from each plant. The pellets were resuspended in PBS and filtered with 22
m syringe filters to remove aggregation and non-exosome particles. The population of PDE
sizes ranged from 197.2 nm ± 6.2 for grapefruit, 154.7 nm ± 3.5 for garlic, and 187.3 nm ± 6.8
for carrot PDEs as determined by dynamic light scattering (DLS) (Figure 5.1A). The charge of
the PDEs was determined to be -19.7 mV ± 6.6 for grapefruit, -28.31 mV ± 6.7 for garlic, and
0.63 mV ± 0.4 for carrot PDEs. The total protein concentration was determined using a DC assay. The resulting concentrations were all significantly high allowing further experiments to be
conducted. The AFM data further confirmed the sizes of the PDEs showing a nanosized population. The results correlated well with the dynamic light scattering data. As shown in Figure 1B,
C, and D, grapefruit, garlic, and carrot PDEs have a homogenous distribution. AFM and TEM
showed clearly that PDEs sizes were all around 95 – 127 nm confirming the validity of our extraction process.
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Figure 5.1: Optical and physical characterization of exosomes extracted grapefruit,
garlic, and carrot
A) Size and index were determined using a 90Plus Particle Sizer (exosomes were isolated using
differential ultracentrifugation). B, C, D) AFM samples were prepared using a stock 100 g/ml
of plant derived exosomes.
5.3.2

Lipid and Protein analysis demonstrates distinct lipid formulations and protein
cargo for grapefruit, garlic, and carrot

Grapefruit derived exosomes were enriched with monogalactosyldiacylglycerol
(MGMG), phosphatidylcholine (PC), and phosphatidylinositol (PI) (Figure 5.2A). Garlic derived
exosomes were enriched with digalactosyldiacylglycerol (DGDG), phosphatidylcholine (PC),
and phosphatidic acid (PA) (Figure 5.2B). Carrot derived exosomes were enriched with digalactosyldiacylglycerol (DGDG), monogalactosyldiacylglycerol (MGMG), and phosphatidic acid
(PA) (Figure 5.2C). MGMG is present in both grapefruit and carrot in high abundance. PC is
present in both grapefruit and garlic derived exosomes in high abundance. DGDG accounts for
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most of the carrot derived exosome membrane and is present in garlic and carrot derived exosomes. Garlic and carrot derived exosomes also show >10% PA within their lipid membrane. PI
is present in all PDEs but is found in its greatest abundance in grapefruit derived exosomes. The
protein data collected shows that grapefruit contains 44 unique proteins, garlic contains 312
unique proteins, and carrot contains 51 unique proteins. Of these proteins, only 5 are shared
across all the PDEs: GAPDH, keratin type I cytoskeleton 9, karatin type II cytoskeleton 1, serum
albumin, and vitronectin. As shown, most of the shared proteins have structural function besides
GAPDH and serum albumin. The PDEs also carry a significant array of proteins which have
been associated with cell functions ranging from proliferation, adhesion, and migration in addiction to proteins involved in transcription and metabolism Figure 5.2A-C. Thus, PDEs share common unique protein cargo of various functionality to that of mammalian derived exosomes as
seen in literature and our previous study with CRC-derived exosomes.
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Figure 5.2. Plant derived exosomes exhibit unique lipid and protein profiles.
Lipids from plants were extracted using chloroform and washed with 1 M KCl. Samples were
analyzed on MS/MS with a collision cell between the two mass specs (Applied Biosystems API
4000 and an Applied Biosystems Q-TRAP) after electron spray introduction. Proteins were analyzed by tandem mass spectrometry on a Q-Exactive Orbitrap. A) grapefruit, B) garlic, C) carrot.
The lipids present Digalactosyldiacylglycerol (DGDG), Monogalactosyldiacylglycerol
(MGMG), Phosphatidylglycerol (PG), Lysophosphatidylglycerol (LysoPG), Lysophosphatidylcholine (LysoPC), Lysophosphatidylethanolamine (lysoPE), Phosphatidylcholine (PC), Phosphatidylethanolamine (PE), Phosphatidylinositol (PI), Phosphatidylserine (PS), and Phosphatidic
acid (PA). Proteins were separated by function: Inflammation, Cell Cycle/Mobility, Structure,
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Coagulation/Adhesion, Endocytosis/Exocytosis, Apoptosis, Misc. Proteomic data provided as
additional file: Plant Derived Exosome Proteomic Data
5.3.3

PDEs exhibit no cytotoxicity of HepG2 cells

The cytotoxicity on the cell lines were tested in vitro on HepG2 cells to determine the biocompatibility and treatment range for the PDEs. The cells showed no toxicity on HepG2 from
50 – 300 g PDE treatments (Figure 5.3A-C). Grapefruit and carrot PDEs exhibited no cytotoxicity remained above 80% viability for treatments at 500 g; however, 30% cytotoxicity was observed in the 500 g garlic PDE treatment. Similarly, toxicity was measured at 100 g PDE
treatments for the Raw 264.7 and Caco2 BBe which resulted in only toxicity present in the
grapefruit PDE treatment on Raw 264.7 cells and all other treatments remained over 80% cell viability (Supplemental Figure 1A, D). We demonstrated that PDEs were biocompatible and
largely non-toxic to any of the cells tested. The results showed that PDEs could be largely used
and administered in living cells.

Figure 5.3: Cytotoxicity of PDEs on HepG2 cells
Cell viability on cells (percentage over control) after overnight supplementation of 100 g/mL
of plant derived exosomes exhibited no significant toxicity on mammalian cell lines. a) HepG2
b) Raw264.7 c) Caco2. (MTT proliferation assay was used to determine the cytotoxicity. n = 8)
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5.3.4

Fluorescent PDEs visualization and flow cytometry analysis HepG2 cells shows
significant uptake of PDEs

To determine the uptake of the PDEs in vitro, a combination of fluorescent microscopy
and flow cytometry was performed using fluorescent labeled PDEs in different cellular conditions. PDEs were readily uptaken into HepG2 cells for all treatment conditions (Figure 5.4A, B).
Both microscopy and flow cytometry data indicate that the level of PDE uptake was not significantly altered with LPS or PA treatment. Similarly, Raw 264.7 cells readily up took the PDEs as
was expected for a macrophage [222] in all conditions tested with no observable difference in
uptake on Raw 264.7 cells between non-LPS and LPS stimulated (Supplemental Figure 2A).We
noticed a slight uptake of grapefruit PDEs non-LPS treated and garlic PDEs LPS treated Caco2
BBe cells (Supplemental Figure 2B).

Figure 5.4: HepG2 cells exhibits significant uptake of plant derived exosomes.
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Fluorescent Microscopy of HepG2 cell lines supplemented with 100 g/ml coumarin 6 labelled
plant derived exosomes with or without LPS (1:100) induced inflammation and 50 g/ml PA. a.
Fluorescent PDEs visualization Red: cytosol, Blue: nucleus, and Green: plant derived exosomes.
b. Flow cytometry analysis of PDEs: Pink: Control, Blue: PDE, Orange: PDE + PA, Green: PDE
+ PA + LPS.
5.3.5

PDEs reduced inflammatory markers on Caco2 BBe, Raw 264.7, and HepG2
cells stimulated by LPS

PDEs on macrophage Raw 264.7 cells
Raw 264.7 cells showed a decrease in expression of CD98, NFB, TNF , and TGF
 (Supplemental Figure 2C). NFB is reduced to roughly below 40% for the LPS supplemented
and non-supplemented samples. TGF  was decreased >10% for the garlic and carrot LPS supplemented samples. TGF  expression was also increased for all PDEs for non-LPS stimulated
samples. Increased expression of TGF  in macrophages has been shown to inhibit the expression of pro-inflammatory mediators [223, 224]. The expression of TNF  was reduced by 30%
in the LPS supplemented samples. Interestingly, we noticed that PDEs also down regulated the
expression of CD98. MMP9 expression was increased for the grapefruit and carrot non-stimulated and grapefruit garlic LPS stimulated samples.
Quantitative PCR data showed an increase in mRNA levels for CD98 for LPS stimulated
and non-stimulated which conflicted with the Western blot results reported (Supplemental Figure
2B). There is a decrease in mRNA levels for TNF  and IL6 for all treatments non-LPS and LPS
stimulated. TNF  showed similar trends for the expression. IL-8 showed a decrease in mRNA
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levels for all PDE treatments. IL-6 showed decreased mRNA levels for grapefruit and garlic LPS
stimulated and garlic and carrot non-stimulated samples.
PDEs on Caco2 BBe cells
Caco2 BBe cells did not exhibit a distinct uptake in PDEs as seen in Supplemental Figure 2B. However, there were biological effects of the PDE treatment. There is a significant reduction in the LPS stimulated sample for CD98 treated with carrot treatment. TGF  expression
was reduced for all treatments with >40% of expression remaining for non-stimulated garlic and
carrot and >50% to for the LPS stimulated samples. TNF  expression was lowered only for the
garlic non-stimulated sample. There was not a significant decrease on NFB expression. MMP9
expression was only decreased for the LPS stimulated carrot sample. TNF  expression is reduced >50% expression. NFB expression is reduced >50% for the garlic non-stimulated and
the LPS stimulated grapefruit and garlic samples.
The qPCR data showed altered expression for TNF , IL-6, and IL-8. TNF  mRNA
levels were significantly reduced for all treatments. IL-8 mRNA levels were decreased for the
non-stimulated garlic and carrot samples. IL-6 was decreased for the non-stimulated garlic samples. The qPCR results for CD98 was increased for all non-stimulated samples but unaffected
for the LPS stimulated.
PDEs on HepG2 cells
To investigate the anti-inflammatory properties of the PDEs on HepG2 cells qPCR and
Western blot experiments were performed and are depicted on Figure 5.5A, B. CD98 mRNA expression is consistently downregulated with all PDE treatments with garlic PDEs exhibiting the
most significant reduction at 50% less than the control. Inflammatory cytokines TNF α, INF γ,
IL1β, and IL6 exhibited similar reductions in mRNA levels with all PDE treatments with levels

95
similar and less than the control levels. There were also notable decreases in mRNA levels for
Cox2 and TGFβ. MMP9 was only consistently reduced for the garlic and carrot PDE treatments.
Western blot results depicted a reduction in CD98 expression which correlated with the
PCR results. TNF  expression was heavily reduced for all treatments. NFB expression shows
a reduction in the control garlic and LPS grapefruit and garlic treatments. TGF  is not consistent with the PCR data and shows no significant increases or reduction in all samples but the
control grapefruit treatment. Interestingly MMP9 is reduced in all LPS PDE treatments and
doesn’t change from the control in the control PDE treatments.

Figure 5.5: Anti-inflammatory effects of plant derived exosomes on HepG2 cells.
HepG2 cells were treated with 100 mg/mL of plant derived exosomes overnight and then stimulated with or without LPS for 4 hours. A) Quantitative PCR (qPCR) analysis of HepG2 cells
treated with plant derived exosomes with or without LPS using stock cDNA of samples. Control
treatments with plant derived exosomes were normalized to the control. LPS treatments with
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plant derived exosomes were normalized to the LPS treatment. B) Primary antibody incubation
was carried out at 1:500 CD98, 1:1000 TNF a, 1:1000 NF Kappa b, and 1:4000 GAPDH overnight at 4oC followed by secondary antibody at 1:4000 for 1 hour at ambient temperature. Blocking was carried out with 5% nonfat milk (CD98: %10 BSA).
5.3.6

Palmitic Acid Induces the Gene Expression of CD98, Integrin 1, and FAK

To access the role of CD98 in steatosis in vitro, Palmitic acid (PA) was used to mimic lipid accumulation in HepG2 cells. Palmitic acid was incubated for 24 hours at 0.1-0.4 mM on
HepG2 cells to determine an acceptable treatment concentration. All treatments resulted in increased gene expression of CD98, integrin 1, and FAK (Figure 5.6A). Palmitic acid treatments
at 0.1 and 0.2 mM produced a 1.7 fold increase CD98 mRNA, a 1.6 fold increase in integrin β1
mRNA, and a 1.6 fold increase in FAK mRNA in the 0.1 mM PA treatment. The concentration
chosen to carry out subsequent experiments was determined to be 0.1 mM palmitic acid over a
period of 24 hours to induce the CD98 expression. Western blot and qPCR results confirmed the
upregulation of CD98 and FAK with PA treatment (Figure 5.6B, C). It is notable that siRNA
CD98 transfection prior to stimulation with PA and LPS attenuated the upregulation of CD98,
FAK, Shc, NFκB, p44/42 MAPK, and p38 MAPK. Interestingly, CD36 expression is returned to
normal levels as a result of the transfection. Thus CD98 play an important role in in downstream
expression of proteins involved in the CD98-integrin pathway.
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Figure 5.6. HepG2 cells were treated with palmitic acid exhibit increased gene expression for CD98, integrin 1, and FAK.
(A) HepG2 cells were treated with 0.1-0.4 mM palmitic acid for 24 hours. Treatments were normalized to the control treatment without palmitic acid. (B) Western blot of HepG2 cells and
HepG2 cells transfected with CD98 siRNA were treated with 0.1 mM palmitic acid for 24 hours.
(C) qPCR of HepG2 cells and HepG2 cells transfected with CD98 siRNA were treated with 0.1
mM palmitic acid for 24 hours.
5.3.7

Plant Derived Exosomes Reduce the Expression of CD98, FAK, Shc, Fyn,
NFB, p38 MAPK, and P42/44 MAPK

The gene expression data obtained from PCR experiments is presented on Figure 5.7B.
The gene expression of CD98, integrin 1, FAK, p38 MAPK, shc, H-RAS, and R-RAS were upregulated with both PA and PA/LPS treatments. LPS was added to the palmitic acid incubation
to determine if LPS could produce NAFLD-like expression quicker through the upregulation of
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pro-inflammatory cytokines. CD98 gene expression is reduced with the post PDE treatment with
the most potent being with grapefruit. Integrin 1 showed significant changes primarily in grapefruit treated samples. FAK expression was also reduced primarily for the grapefruit samples. Shc
showed reduction for the PA carrot, and all PA/LPS plant treatments. H-RAS presented reductions in the PA grapefruit and carrot and PA/LPS grapefruit samples. R-RAS expression was reduced for the PA grapefruit sample.
CD98 protein expression was upregulated with both PA and PA/LPS stimulation. Reductions in CD98 expression were observed primarily in the PA plant treatments and not in the
PA/LPS plant treatments. This did not correlate well with the qPCR data and must be repeated to
confirm the results. Integrin 1 did not show distinct expression changes from the control sample. Interestingly, the PA treated sample is reduced despite the upregulation of gene expression.
FAK expression is upregulated in both PA and PA/LPS samples and all plant treatments downregulated the protein expression. R-RAS was not upregulated with PA and PA/LPS, but expression was not observable for the PA grapefruit and PA/LPS garlic and carrot samples. AKT garlic
samples were not affected by PA, PA/LPS, or plant treatments. It may be interesting to check the
phosphorylated species of AKT to determine in PDEs can affect AKT activation. Shc was upregulated in the PA treatment and not the PA/LPS. The PA/LPS garlic sample was reduced, however, no other PDE treatment demonstrated a significant change which did not correlate to the
gene expression. Fyn was upregulated in only the PA treated sample and reduced expression was
observed for all PA plant treatments. The PA/LPS treatments resembled the PA/LPS control expression. The expression of p44/p42 MAPK was upregulated in the PA and PA/LPS samples.
The PA grapefruit and garlic and PA/LPS carrot samples had reduced expression comparable to
the control. The upregulation of p38 MAPK with PA treatment and there is significant reduction
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in in all plant treatments. PA and PA/LPS increased the expression of p85/p55 PI3K with reduced expression observed in all treatments. The expression of p100 PI3K was upregulated for
PA/LPS with significant reductions only observed for PA/LPS garlic and carrot samples. The PA
treated sample did show slight upregulation, however, PA plant treatments were upregulated to a
greater extent. The expression of p100 PI3K was upregulated with PA and PA/LPS. PDE treatment did not have an overall effect on p100 PI3K.

Figure 5.7: Effects of plant derived exosomes on the CD98-Integrin pathway on HepG2
cells.
HepG2 cells were treated with 0.1 mM of PA or PA/LPS for 24 hours followed by treatment
with 50 g/mL of plant derived exosomes for 24 hours. A) Primary antibody incubation was carried out at 1:500 (CD98, integrin 1, R-RAS, H-RAS, Fyn, CD36), 1:1000 (NF Kappa b, FAK,
AKT, Shc, p38 MAPK, p85/p55 PI3K, P100 PI3K, P100 PI3K), 1:2000 p44/p42 MAPK, and
1:4000 GAPDH overnight at 4oC followed by secondary antibody at 1:4000 for 1 hour at
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ambient temperature. Blocking was carried out with 5% nonfat milk. B) Quantitative PCR
(qPCR) analysis of HepG2 cells treated with plant derived exosomes with or without PA or LPS
using stock cDNA of samples. Control treatments with plant derived exosomes were normalized
to the control.
5.3.8

Weights of mice fed HFD and garlic PDE gavage

To access the therapeutic and preventative effects of garlic PDEs mice were given an
HFD for a duration of 9-10 weeks with a post and con-current treatment (Figure 5.8A). Mice
steadily gained weight as the diet continued for 10 weeks. Daily gavage of garlic and PBS exhibited weight loss in all mice (Figure 5.8B). Weight loss was more observed in the mice gavaged
garlic derived exosomes for the post-treatment group which was determined to be 45% difference in overall weight gain for the HFD + PDE group (81.7% overall weight gain) from the HFD
group (127% overall weight gain). Weight gain for mice given HFD and garlic PDEs at the same
time were similar to the control mice group given HFD and PBS where the difference in overall
weight gain was 10%. Throughout each treatment regimen mice exhibited similar phenotypes
with no signs of detrimental effects from daily treatments of garlic PDEs.
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Figure 5.8: Mice treated with garlic derived exosomes exhibited similar weight loss trends
to that of the control mice group.
A) Mice were fed an HFD for a period of 9-10 weeks with a daily gavage of 0.5 mg/mL garlic
derived exosomes and 1x PBS after week 8 and throughout HFD for 9 weeks. B) Weight gain
trends for mice recorded periodically though diet and treatment.
5.3.9

Biodistribution study relative to the liver

The biodistribution at the cellular level within the liver using flow cytometry analysis.
Flow cytometry, noted in Figure 5.9 showed that C6 labelled garlic PDEs mainly target hepatocytes (FITC+ albumin+, Figure 5.9C) and macrophages like cells (FITC+ CD11b+, Figure 5.9C),
but not dendritic cells (FITC+ CD11c+, Figure 5.9D). We noticed that liver cells from mice suffering NAFLD and on a LFD uptake NPs differently when healthy and hepatocytes from HFD
and LFD treated mice had nearly two times more NPs uptake than cells in normal conditions respectively, 8.72 vs 15.0 and 15.1 (Figure 5.9B). Alternatively, macrophages like cells exhibited a
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decrease in uptake of labelled garlic PDEs when on HFD and LFD when compared to normal
conditions which were 5.18 vs 3.21 and 1.01 respectively. Dendritic cells were not significantly
“stimulated” by HFD or LFD with very low NPs uptake (below 1 for both conditions, Figure
5.9C, D). We also noticed that HFD and LFD induced proliferation in the liver which increased
from 44.7 to 77.2 and 79.9 respectively (Figure 5.9A).

Figure 5.9: Flow cytometry analysis indicating that gavage of garlic PDE is significantly
uptaken by hepatocytes compared to macrophage-like cells and dendritic cells.
Representative FACS plots illustrating the gating strategy utilized to define live cells hepatocytes
macrophages like cells, and dendritic cells for mice gavaged daily with garlic PDE (5 mg/mL,
100 µL) and receiving or not HFD or LFD. Cells were gated as followed for hepatocytes CD45-
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MHC class II- F4/80−CD11b-CD11c-albumin+, macrophages-like cells CD45+MHC class
II+F4/80+CD11b+CD11c- cells and dendritic cells CD45+MHC class II+
F4/80−CD11b+CD11c+. Values represent means ± SE. Data are representative of n=5 mice per
group. **P < 0.01, *P < 0.05 and NS, not statically significant
5.3.10 Gene expression of inflammatory and NAFLD markers on liver and colon tissue
The therapeutic potential of garlic PDEs were tested on mice 8 weeks into an HFD feeding regimen. The gene expression for the mice treated with garlic derived exosomes demonstrated reduced gene expression (~40 -50% reduction) for inflammatory cytokines (TNF , IL6,
INF  IL1) when compared to the mice gavaged with PBS This demonstrated that garlic could
potentially decrease inflammation associated to long term NAFLD. MMP9 and MMP2 gene expression was reduced by ~40% which could also be a mechanistic for decreased CD98 function
which is also seen to be reduced by ~40%. PPAR  and  are reduced by ~40% which are common targets for NAFLD treatments. Interestingly, we find that CD36 is reduced which could
suggest that PDEs are affecting fatty acid transport in the liver. This result can be attributed to
the decrease in inflammatory cytokine expression of TNF and IL1 which have been correlated to
the upregulation of fatty acid translocases in the liver [225]. TGFβ was reduced by 60%. ACAT
and SCD were reduced by 60% and there was an observable increase in APOA and ABCA
mRNA levels. Western blot data confirmed the downregulation of CD98, CD36, and TGFβ.
Similar downregulation was observed for FAK, Shc, NFκB, and Cav-1.
The colon demonstrates similar results in only MMP9, and IL1. CD36 is completely
knocked out. PDEs affected the organs without a set pattern. Further study would have to be
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performed to determine if the PDEs are directly accumulating in the liver and thus giving its affects or the PDEs are directly affecting both organs in a different way.

Figure 5.10. Liver gene expression of mice fed with high fat diet with daily oral administration of garlic derived exosomes.
Mice were fed a high fat diet for 10 weeks followed by 20 days of daily gavage of 0.5 mg of garlic derived exosomes. Livers were harvested after day 90. The gene expression was normalized
to the high fat diet mice group. (Graphs shown in Appendix Figure 6-3)
To test the preventative and therapeutic potential of garlic PDEs in the development of
NAFLD, HFD fed mice were given garlic PDEs during the duration of a 9 weeks. Mice were
sacrificed at 3 weeks, 6 weeks, and 9 for analysis. CD98 mRNA levels were stably downregulated when compared to the NAFLD + PBS treated group with an 80%, 30%, and 60% decrease
for week 3, 6, and 9 respectively. Reductions in anti-inflammatory cytokines (INF γ, TNFα, IL6,
and IL1β) were also observed in the 6 and 9 weeks samples which all exhibited a 40-80%
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reduction in mRNA levels compared to the untreated control. Interestingly, only INF γ and IL6
were reduced for the 3 week group (10% and 80%), but there was an observable upregulation in
TNFα and IL1β (9 fold and 14 fold). CD36 was continuously downregulated from 20%, 30%,
and 75% reductions for each group. MMP9 exhibited an initial upregulation (3 fold) at 3 weeks
followed by a 10% and 100% reduction for 6 and 9 weeks respectively. MMP2 and PPARγ was
stably downregulated by 50-100% for each group. Integrin β3 was initially upregulated (7 fold)
at 3 weeks followed by over 80% reductions for week 6 and 9.
CD98 protein levels were significantly reduced for the GDE treated groups when compared for the PBS groups for all weeks confirming the qPCR results. Similarly, integrin β1 and
β3 were comparably downregulated with GDE treatment. GDEs downregulated the expression of
CD36 confirming the qPCR results. PI3K p100β, PI3k p100α, and p44/42 MAPK expression
levels were downregulated for each week for the GDE groups. Initially, MMP2 and Shc levels
were increased for the 3 week group but were then downregulated for the 6 week and 9 week
groups. FAK expression was initially downregulated during week 3, then upregulated during
week 6, followed by similar expression levels at week 9. Finally, NFκB levels were consistently
downregulated during week 6 and 9.
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Figure 5.11. Liver gene and protein expression of mice fed with high fat diet with
daily oral administration of garlic derived exosomes post NAFLD.
Mice were orally administered 0.5 mg of garlic derived exosomes for 3 weeks, 6 weeks, and 9
weeks. A) Tabulated qPCR results for the mice groups. Graphs represented in Appendix Figure
6-5. B) Western blot results for PBS and GDE gavaged groups.
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5.3.11 Hematoxylin and Eosin Y staining of liver tissue revealed that garlic PDEs reduced and prevented steatosis in HFD mice
We examined high fat diet-induced histological changes (i.e., accumulation of lipid vacuoles in the cytosol) in liver tissues from mice treated with the garlic PDEs. Microscopic analyses
of H&E from these mice revealed the presence of lipid vacuoles (hepatic steatosis) in livers from
high fat diet-fed mice gavaged with 1xPBS, but not with the mice gavaged with garlic PDEs. Lipid vacuoles are indicated by arrows and are in the circled areas (Figure 5.12A). Daily gavage of
1xPBS and garlic PDEs during HFD revealed limited steatosis for both the 1xPBS and garlic
PDEs group at 6 weeks. There was a significant increase in steatosis in the 1xPBS gavaged
group and steatosis was significantly prevented/reduced in the garlic PDE group (Figure 5.12B).

Figure 5.12. Mice treated with garlic derived exosomes exhibit decreased lipid vacuoles.

108
A) Mice were orally administered 0.5 mg of garlic derived exosomes for 20 days after high fat
diet for 70 days. B) Mice were orally administered 0.5 mg of garlic derived exosomes for 3
weeks, 6 weeks, and 9 weeks. Liver tissues were stained with H&E. Scale bar, 100 m. (H&E
20x)
Discussion
Our study expands on the previous reports of exosome-like nanoparticles from plants
and their unique communication with mammalian cells. Previous studies have interrogated the
communication of plants with macrophages and stem cells [60, 62]. We chose plants that were
well known to be beneficial for a healthy liver [226-228]. The choices were narrowed to plants
that had anti-inflammatory properties [219, 220, 229] to interrogate if the PDEs could be used
to reduce liver inflammation. Our aim was to investigate if the PDEs from grapefruit, garlic,
and carrot have an efficient effect on liver cells through the modulation of the CD98-integrin
pathway. We demonstrated they are readily uptaken into the HepG2 cells. Mammalian and
plant derived exosomes have been shown to share common physical characteristics: size, lipids,
proteins, and RNA [60, 61, 230-232] and our PDEs shared common characteristics. Our results
further confirmed that the sizes were comparable to previously reported. The PDEs from each
plant had a unique biological effect on the mammalian cells chosen in this study.
The other markers that were probed in the experiment were chosen due to their role in
inflammation related to nonalcoholic fatty liver disease. Tumor necrosis factor alpha (TNF ) a
pro-inflammatory cytokine that has been implicated in insulin resistance and the pathogenesis
of nonalcoholic liver disease [233]. Nuclear factor kappa-light-chain-enhancer of activated B
cells (NF B) regulates the activation of genes directly involved in inflammation [234]. Transforming growth factor beta (TGF ) plays a direct role in inflammatory response and can be
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found to be significantly elevated in nonalcoholic liver disease [235, 236] Matrix metalloproteinase (MMP)-9 has been implicated with liver fibrogenesis [237]. Taken together, the proteins chosen for this study are dysregulated in various liver diseases. Cox-2 are pro-inflammatory forming prostanoids and are often a target for alleviating inflammation in diseases [238,
239]. And our aim was to show that specific PDEs can regulate the expression of these markers
after LPS induced inflammation.
Our study further showed the anti-inflammatory properties of PDEs in regards to macrophages with slight decreases in expression of TNF , NF B, and decrease in mRNA levels
of IL-6. Grapefruit extracts have been shown to reduce TNF  expression which supports our
results [240]. Macrophages have already been show to take in PDEs [60, 61] by protecting
from DSS stimulation and reducing TNF  and IL1 through the reduction of HO-1 expression. We thus confirm this in Raw 264.7 which presented similar anti-inflammatory effects
through grapefruit, garlic, and carrot PDE treatment after LPS stimulation. In this regard, PDEs
could protect macrophages from LPS induced inflammation. Interestingly MMP9 and TGF
 expression was also affected suggesting that PDEs alter growth pathways in macrophages in
addition to their anti-inflammatory properties.
Caco2 BBe and HepG2 were used to demonstrate the specific targeting of the PDEs. We
demonstrated that PDEs were significantly taken up by the liver cells rather than the colon
cells. This may be partially due to the nature in which liver cells function. We did not expect
the colon cells to interact with the PDEs at the same level as the liver cells. However, we could
not omit that a previous studies demonstrated that PDEs can affect the colon [62]. Gene expression of inflammatory cytokines were significantly reduced. However, our Western blot
data did not demonstrate similar trends. Expression of TGF  was the only notable alteration
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with the treatment of PDEs. The cause of these alterations must be further investigated. Thus,
from our data, gene expression of inflammatory cytokines is significantly reduced in Caco2
BBe cells despite the low uptake of the PDEs.
Liver cell targeting for inflammation was the primary aim for the initial study. We
demonstrated that grapefruit, garlic, and carrot derived exosomes presented reduction in TNF,
IL6, NFB, and cox-2 in addition to reduction in CD98 expression during LPS stimulation.
CD98 has been implicated to be overexpressed during inflammation in the liver and is a known
ligand for galectin-3 which is also overexpressed during inflammation [241]. Overexpression of
intestinal CD98 has been linked to the upregulation of inflammation [242]. The PDEs chosen for
the experiment downregulated CD98 in both protein and gene expression which supported our
choice to target the CD98-induced integrin 1 signaling pathway to determine the consequence
of the downregulation.
Palmitic acid was used as the FFA to produce our in vitro NAFLD model in HepG2
cells. Palmitic acid is one of the most common FFA found during NAFLD next to oleic acid and
is commonly used for this model [243]. We determined that CD98, integrin 1, and FAK expression was upregulated with addition of palmitic acid over an array of concentrations. The
data we collected demonstrated that CD98 expression did not have a distinct effect on integrin
1 expression. This is supported by a previous study that showed that downregulation of CD98
only caused defects in integrin 1 signaling as CD98 may play a role as a ‘molecular facilitator’
for integrin binding to its ligands [72]. We observed that NFB is reduced for the treatments
with palmitic acid and LPS. This supported by our previous findings for the LPS studies. Interestingly, p38 MAPK, which reacts to stress to stimulate the production of NFB [215, 244], is
reduced with all treatments suggesting that the PDEs are effectively targeting this pathway. This
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is further demonstrated by the reduction in p44/p42 MAPK which is involved in stress induced
angiogenesis and stimulation of growth factors [245]. This downregulation could be a consequence of impaired integrin 1 signaling, but we cannot rule out the possibility that the PDEs
carry small molecules that target this pathway specifically. It has been reported that grapefruit
impaired breast cancer cell proliferation through the use of naringenin [246], diallyl trisulfide
from garlic inhibited the ERK/MAPK pathway to impair breast cell migration and invasion and
targeted the NFB pathway [220, 247], and oil extracts from carrots have been shown to inhibit
the MAPK pathway [248]. Perhaps the PDEs also carry these molecules that target MAPK rather than the downregulation of MAPK being due to altered integrin signaling.
Another interesting finding is that the PDEs reduced the expression of FAK. FAK activation plays an integral role in integrin 1 signaling and regulation [249]. Targeting FAK has
been of keen interest over the years as a therapeutic target for cancer because of its major role in
tumor progression [168]. Similarly, shc expression is also downregulated. Shc has been implicated with the motility and invasiveness of cancer and the progression of nonalcoholic steatohepatitis [250, 251]. Downregulation of shc could explain the reduction of MAPK since it plays
a major role in MAPK activation [252]. Fyn expression exhibited slightly reduced expression
when compared to the palmitic acid control. Fyn has been shown to have anti-apoptotic through
the activation of akt [253]. Therefore, inhibition of fyn has garnered great interest for cancer
therapy. H-RAS and R-RAS were reduced for palmitic acid grapefruit treated and palmitic
acid/LPS garlic and carrot treated. The data for RAS did not show an upregulation for any of the
stimulations. However, the reduced expression for these treatments are worth noting for further
investigation as RAS dysfunction has been implicated to tumorigenesis when mutated [254].
The data we obtained gives rise to the possibility of using our PDEs as a cancer therapy in
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addition to using PDEs to treat inflammation. In support of this, lemon derived nanovesicles
have recently been shown to induce apoptosis and inhibit tumor growth [63]. It is possible that
utilizing PDEs to target the integrin 1 signaling pathway as a method to decrease tumor cell
proliferation, migration, and adhesion.
Our data also suggests that the PDEs did not affect the integrin 1 signaling pathway at
PI3K or Akt with neither exhibiting changes in expression levels with treatments. Interestingly,
MMP-2 gene expression is downregulated for the treatments which could serve as another
method for PDE regulation of the CD98 and integrin 1 interaction. As stated before , the downregulation of CD98 reduces MMP-2 expression that can cleave galectin-3 to increase binding to
gycoconjugates which causes accumulation of extracellular galectin-3 since it cannot interact
with the heterocomplex formed by CD98hc, CD147, and 1-integrins which then limits integrin-dependent and FAK activation [76]. Similarly, MMP9 is reduced for the palmitic PDE treatments, but not the palmitic acid and LPS treatments. This was not expected as p38 MAPK can
induce MMP-9 expression [255]. Thus we cannot rule out the possibility that MMP9 is cleaving
galectin-3 to activate CD98 [256]. Further investigation of the effect of the reduced gene expression of MMP-2 and -9 will be needed to elucidate how PDEs affect the activation of CD98-induced integrin 1 signaling pathway.
Conclusion
PDE treatment exhibited anti-inflammatory effects on liver and macrophages cells stimulated with LPS. Specific uptake of PDEs by liver cells was demonstrated as HepG2 cells
showed a tremendous PDEs incorporation compared to the Caco2BBE cells. As expected, Raw
264.7, professional phagocytosis cells, showed an important uptake of all PDEs leading to a significant reduction of pro-inflammatory markers. Importantly, HepG2 cells readily uptake each
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PDE mainly garlic PDEs and exhibited anti-inflammatory effects which implicates using PDEs
to treat liver mammalian cells lines could be a new therapeutics tool to treat liver inflammation.
We also presented that plant derived exosomes from grapefruit, garlic, and carrot
demonstrated unique effects on proteins implicated in the CD98-integrin 1 signaling pathway.
PDEs downregulate CD98 expression in HepG2 cells which can activate integrin signaling.
More interesting is that PDEs downregulate FAK expression which plays an important role in
many other signaling pathways and is often a target for anti-tumor therapeutics. Some PDEs
eliminated the expression of some RAS proteins which may play a role in the overall signaling
process. NFB was reduced for all PDE treatments suggesting an anti-inflammatory property for
the PDEs. The reduced MAPK expression with PDE treatment also suggests that PDE treatment
reduced stress on the cells which in turn reduced inflammation and growth signaling. Taken together, we demonstrate that PDEs efficiently reduced CD98, FAK, Shc, NFB, p38 MAPK, and
p44/p42 MAPK to reduce inflammation in LPS and palmitic acid stimulated HepG2 cells. In the
future, the mechanisms of how these effects occur will be analyzed with hopes of developing total synthetic PDEs to enhance their therapeutic potential.
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SUMMARY AND FUTURE DIRECTIONS

The direction of this work was to investigate CD98 and its role in liver disease and its role in
the interaction with colorectal cancer derived exosomes for liver metastasis. To date, little is
known about CD98 and its role in early stages of liver disease such as NAFLD, NASH, and liver
fibrosis. Chapter 2 focused on investigating potential avenues in which CD98 could be upregulated or activated. The major findings were that during steatosis and steatohepatitis CD98 expression is upregulated in histology of patients with those diseases. This was the first direct evidence
that CD98 may be a player in the disease. It is worth noting that while examining the progression
of the liver disease to cirrhosis and hepatocellular carcinoma in the patient histology that the
CD98 upregulation trend was continued. By examining literature, the potential avenues of activation and upregulation involved galectin-3, INF-, integrin v3, and MMP 2/9.
Chapter 3 focuses on utilizing a polymer nanoparticle system to deliver CD98-siRNA to
inflamed cells and the liver of a NAFLD mouse model. The goal of this study was to investigate
what potential role CD98 was playing in the development of NAFLD and liver inflammation.
We found that by downregulating CD98 there was a distinct anti-inflammatory effect on HepG2
cells. In addition, treatment via tail vein injection significantly successfully reduced CD98 upregulation during the development of NAFLD. Serum levels of ALT, cholesterol, triglycerides, and
glucose were significantly reduced indicating the decrease in NAFLD markers. This demonstrated that liver health was maintained throughout the high fat diet. The most interesting finding
was that this downregulation of CD98 played a novel anti-fibrotic and anti-steatosis role with the
prevention of profibrotic markers and lipid vacuoles in the NAFLD mouse model.
Chapter 4 shifted focus to the role of CD98 in HepG2 cells when treated with CRC-derived
exosomes. As previously mentioned, CD98 acts as a molecular facilitator for integrin signaling
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and integrin expression is upregulated in tumors and in stages of metastasis. We demonstrate that
when HepG2 cells are treated with Caco2 BBe exosomes integrin 1 and 3 were upregulated
with no effect on CD98 expression. Downstream proteins in the integrin signaling pathway
(PI3K and MAPK isoforms, FAK), NFB, and IL-6 were upregulated after stimulation. We later
uncovered that colocalization of CD98 with integrin was ‘clustered’ thereby hinting at increased
CD98 signaling. The early stages of this study demonstrate that CRC derived exosomes could
potentially modulate CD98 activation to increase integrin signaling. Future studies of this section
would be to examine other characteristics of the exosomes (nucleic acid cargo) and to treat on
primary cell lines to see if this increase tumorigenic phenotype would still be observed upon
stimulation.
Chapter 5 focuses on treating NAFLD with a focus on CD98 using natural nanovectors from
plants. PDEs from grapefruit, garlic, and carrot were successfully isolated and were biocompatible for the treatment concentrations. PDEs exhibited significant uptake into the HepG2 and
hepatocytes in the liver. PDEs exhibited anti-inflammatory properties against LPS treated cells
while downregulating CD98. We chose to continue with garlic derived exosomes since it downregulated CD98 the most in both the inflammatory and steatosis in vitro model. Garlic derived
exosomes downregulated CD98 and proteins downstream of the CD98-integrin pathway both in
vitro and in vivo. In addition, GDEs exhibited anti-inflammatory and anti-steatosis properties in
the high fat diet mice. The key findings were that the treatments downregulated isoforms of
MAPK and PI3K, NFkB, and proinflammatory cytokines in addition to CD98. Another noteworthy protein that downregulated was CD36 which may attribute to its antisteatotic properties.
To further examine if CD98 is one of the key targeted proteins with the garlic exosome
treatment a knockout study of CD98 following the same treatment regimen would be necessary.
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Similarly, this would also be beneficial to knockout CD98 and examine the knockout mice during the high fat diet. Another step would be to investigate the activity of each downstream protein of the CD98-integrin pathway. Finally, enhancing and utilizing the plant exosomes as therapeutics by loading therapeutics or stripping unnecessary components could give rise to novel
NAFLD treatment.
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APPENDIX
Appendix Table 1. Human and Mouse Primers (h = human and m = mouse)
Gene
hGAPDH
hCD98
hIntegrin 1
hFAK
hH-Ras
hR-RAS
hShc
hp38MAPK
hMMP2
hMMP9

Forward
5'-TTGGTATCGTGGAAGGACTCA-3'
5’-GCTTGCAGCCAAAACTCCAG-3’
5’-GAAGGGTTGCCCTCCAGA-3’
5’-GAAGCATTGGGTCGGGAA-3’
5’-TTTGAGGACATCCACCAGTACA-3’
5′-GGCAGATCTGGAGTCACAGC-3′
5'-GGGCGAGTCCTGATAAAACA-3’
5’-GCCCAAGCCCTTGCACAT-3’

Reverse
5’- TGTCATCATATTTGGCAGGTTT-3’
5’-CCAACTACCGGGGTGAGAAC-3’
5’-GCTTGAGCTTCTCTGCTGTT-3’
5’-CTCAATGCAGTTTGGAGGTGC-3’
5’-GCCGAGATTCCACAGTGC-3’
5′-ACGTTGAGACGCAGTTTGG-3′
5’-GTCTGCAGGAAAACCTCTGC-3’
5’-TGGTGGCACAAAGCTGATGAC-3’

5’-CAGGGAATGAGTACTGGGTCTATT-3’
5′-AAGGATCCGACTATGACACCGACCGTCG-3’

5’- ACTCCAGTTAAAGGCAGCATCTAC-3’
5′AAGAATTCGGCGCCGGTAGGGCTGGTA3’
5’-GTCCTTTCAAGGAGAATGGTGC-3’
5’-CTTTATCAGCTGCACATCACTCAGA-3’
5’-GACTTTCTCCTGGTATGAGATAGCAAA3’
5’-TTGCCATTGCACAACTCTTTTC-3’

hCox-2
m36B4
mTNF-α

5’-GGTCTGGTGCCTGGTCTGATGATG-3’
5'-TCCAGGCTTTGGGCATCA-3’
5’-AGGCTGCCCCGACTACGT-3’

mIL-6

5’-ACAAGTCGGAGGCTTAATTACACAT3’
5ꞌ-CACCTCAAGAACATCCAGAGCT-3'
5′- CGGAAGCGCATCGAAGCCATCC-3′
5′-GAGGACAGGCTTTTGATTGC-3′
5'-TCAAGTGGCATAGATGTGGAAGAA-3'
5′-TCATTGCAACTGAGTGG-3′
5`-CTTCTGGCGTGTGAGTTTCCA-3`
5’-CAGGGAATGAGTACTGGGTCTATT-3’
5’-GCGATGAAGAGCATGGTTTAG-3’
5’-GCCTGTCTGTCGGGATGT-3’
5’-GGATTTTAGAGTGGGTGTTTTTTA-3’
5’GGTTTGGAGATGGTTATACAATAGTTGT
3’
5’-TACTACAAGCCCGGCCTCC-3’
5’-GGAGCCATGGATTGCACATT-3’
5’-CACAGCAGCACATCAACAAG-3’
5’TGAGGCGCTGTCGTCATCGATTTCTCCC3’
5’- AACGAGGCTGGAATTAGCAGAA-3’
5’-CTTGGCACGTATGGCAGCA-3’
5’-CAGGAAGTAAGATGCCTGGAAC-3’

mIL-8
mTGF-β
mCD98
mINF 
mCD36
mMMP-9
mMMP2
mFAS
mPPAR
mPPAR
mABCA

mSCD
mSREBP1
mIL1
mIL10

mCD106
mAPOA
mACAT

5ꞌ-CAAGCAGAACTGAACTACCATCG-3ꞌ
5′-GCAAGCGCAGCTCTGCACGG-3′
5′-ATTCAGTCGCTCCCCAGTG-3′
5'-TGGCTCTGCAGGATTTTCATG-3'
5′- TCATAAGCTCTGTGTCAG-3′
5`-ACTGCACGGTTGAAGC AAAGA-3`
5’-ACTCCAGTTAAAGGCAGCATCTAC-3’
5’-GGCTCAAGGGTTCCATGTT-3’
5’-GGCTTCGTGGATTCTCTTG-3’
5’-CACACCCGATTCCATGTTGAG-3’
5’-TTCCCGGAAACGCAAGTC-3’
5’-CAGCAGTACCAGGGCACCA-3’
5’-GGCCCGGGAAGTCACTGT-3’
5’-GTGCTCATGTCCTCATCCTG-3’
5’- ACCTGCTCCACTGCCTTGCT-3’
5’- CCCTCTTTGACACTCTTAGATGGAA-3’
5’-CCAGAAGTCCCGAGTCAATGG-3’
5’-TTCACCCCCTTGGATGACATT-3’
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Appendix Figure 6-0.1:
Cell viability on cells (percentage over control) after overnight supplementation of 100 g/ml of plant derived exosomes exhibited limited significant toxicity and cells. A) Raw 264.7 D) Caco2 BBe (MTT proliferation assay was used to determine the cytotoxicity. n = 8) Cells were treated with 100 mg/mL of plant
derived exosomes overnight and then stimulated with or without LPS for 4 hours. B,E) Quantitative PCR
(qPCR) analysis of cells treated with plant derived exosomes with or without LPS using stock cDNA of
samples. Control treatments with plant derived exosomes were normalized to the control. LPS treatments
with plant derived exosomes were normalized to the LPS treatment. C, F) Primary antibody incubation
was carried out at 1:500 CD98, 1:1000 TNF a, 1:1000 NF Kappa b, and 1:4000 GAPDH overnight at 4oC
followed by secondary antibody at 1:4000 for 1 hour at ambient temperature. Blocking was carried out
with 5% nonfat milk (CD98: %10 BSA).
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Appendix Figure 6-0.2:
Fluorescent Microscopy of Raw 264.7 and Caco2 BBe cell lines supplemented with 100 g/ml
coumarin 6 labelled plant derived exosomes with or without LPS (1:100) induced inflammation.
A) Raw 264.7 PDE uptake B) Caco2 BBe uptake. Red: cytosol, Blue: nucleus, and Green: plant
derived exosomes.

133

Appendix Figure 6-0.3: Liver gene expression is reduced for inflammatory and markers
for NAFLD for high fat diet mice with garlic derived exosome treatment.
Mice were orally administered 0.5 mg of garlic derived exosomes for 3 weeks after high fat diet
for 10 weeks. Gene expression was normalized to the high fat diet mice.
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Appendix Figure 6-0.4: Colon gene expression demonstrated reduction in IL1B, MMP9,
and IL8 for high fat diet mice with garlic derived exosome treatment.
Mice were orally administered 0.5 mg of garlic derived exosomes for 2 weeks after high fat diet
for 10 weeks. Gene expression was normalized to the high fat diet mice.
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Appendix Figure 6-0.5: Liver gene expression is reduced for inflammatory and markers
for NAFLD for high fat diet mice with garlic derived exosome treatment.
Mice were orally administered 0.5 mg of garlic derived exosomes for 3, 6, and 9 weeks while on
a high fat diet. Gene expression was normalized to the pbs treated high fat diet mice.

